Vanda Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Vanda Pharmaceuticals Inc together

Penke I guess you are interested in Vanda Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Vanda Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Vanda Pharmaceuticals Inc

I send you an email if I find something interesting about Vanda Pharmaceuticals Inc.

Quick analysis of Vanda Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

$9.47

Expected worth in 1 year

$9.78

How sure are you?

72.5%

+ What do you gain per year?

Total Gains per Share

$0.31

Return On Investment

6.0%

For what price can you sell your share?

Current Price per Share

$5.11

Expected price per share

$3.46 - $6.04

How sure are you?

50%

1. Valuation of Vanda Pharmaceuticals Inc (5 min.)

Live pricePrice per Share (EOD)

$5.11

Book Value per Share

$9.47

Intrinsic Value Per Share

$-16.58 - $7.78

Total Value Per Share

$-7.11 - $17.25

My calculation of the intrinsic value of Vanda Pharmaceuticals Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($0.05) 3Y: ($0.16) TTM: ($0.05)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($-0.03) TTM: ($-0.06)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.12	$0.65	$-0.32 - $0.68
2	$-0.70	$1.33	$-0.84 - $0.74
3	$-1.70	$2.04	$-1.35 - $0.79
4	$-3.05	$2.79	$-1.87 - $0.85
5	$-4.73	$3.56	$-2.39 - $0.91
6	$-6.68	$4.36	$-2.91 - $0.97
7	$-8.88	$5.19	$-3.42 - $1.02
8	$-11.28	$6.03	$-3.94 - $1.08
9	$-13.86	$6.90	$-4.46 - $1.14
10	$-16.58	$7.78	$-4.98 - $1.20

2. Growth of Vanda Pharmaceuticals Inc (5 min.)

Is Vanda Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$544.9m	$513.3m	$27.5m	5.1%

How much money is Vanda Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	$627.2k	$1.5m	-$941.5k	-150.1%
Net Profit Margin	0.9%	2.2%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Vanda Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#99 / 1016

Most Revenue
#158 / 1016

Most Profit
#152 / 1016

Most Efficient
#161 / 1016

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc? (5 min.)

Welcome investor! Vanda Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Vanda Pharmaceuticals Inc.

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc?

First you should know what it really means to hold a share of Vanda Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Vanda Pharmaceuticals Inc is $5.11. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Vanda Pharmaceuticals Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Vanda Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $9.47. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Vanda Pharmaceuticals Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.04	-0.8%	0.01	0.2%	0.03	0.5%	0.16	3.1%	0.07	1.3%
Usd Book Value Change Per Share	0.04	0.8%	0.08	1.5%	0.10	1.9%	0.23	4.6%	0.22	4.3%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.04	0.8%	0.08	1.5%	0.10	1.9%	0.23	4.6%	0.22	4.3%
Usd Price Per Share	4.22	-	5.48	-	9.87	-	11.88	-	13.44	-
Price to Earnings Ratio	-25.29	-	130.29	-	23.64	-	37.57	-	-13.96	-
Price-to-Total Gains Ratio	103.08	-	83.39	-	-4.40	-	70.07	-	110.72	-
Price to Book Ratio	0.45	-	0.58	-	1.11	-	1.58	-	44.56	-
Price-to-Total Gains Ratio	103.08	-	83.39	-	-4.40	-	70.07	-	110.72	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	5.11
Number of shares	195

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.08	0.23
Usd Total Gains Per Share	0.08	0.23
Gains per Quarter (195 shares)	15.01	45.67
Gains per Year (195 shares)	60.03	182.66

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	60	50	0	183	173
2	0	120	110	0	365	356
3	0	180	170	0	548	539
4	0	240	230	0	731	722
5	0	300	290	0	913	905
6	0	360	350	0	1096	1088
7	0	420	410	0	1279	1271
8	0	480	470	0	1461	1454
9	0	540	530	0	1644	1637
10	0	600	590	0	1827	1820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	3.0	1.0	0.0	75.0%	10.0	2.0	0.0	83.3%	17.0	3.0	0.0	85.0%	22.0	18.0	0.0	55.0%	27.0	49.0	1.0	35.1%
Book Value Change Per Share	4.0	0.0	0.0	100.0%	11.0	1.0	0.0	91.7%	19.0	1.0	0.0	95.0%	29.0	11.0	0.0	72.5%	39.0	36.0	2.0	50.6%
Dividend per Share	0.0	0.0	4.0	0.0%	0.0	0.0	12.0	0.0%	0.0	0.0	20.0	0.0%	0.0	0.0	40.0	0.0%	0.0	0.0	77.0	0.0%
Total Gains per Share	4.0	0.0	0.0	100.0%	11.0	1.0	0.0	91.7%	19.0	1.0	0.0	95.0%	29.0	11.0	0.0	72.5%	39.0	36.0	2.0	50.6%

Fundamentals of Vanda Pharmaceuticals Inc

About Vanda Pharmaceuticals Inc

https://www.vandapharma.com
Biotechnology
203
2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
Google Maps Bing Maps

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Fundamental data was last updated by Penke on 2024-04-12 21:40:03.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Vanda Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Vanda Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of -5.3% means that $-0.05 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Vanda Pharmaceuticals Inc:

The MRQ is -5.3%. The company is making a loss. -1
The TTM is 0.9%. The company is not making a profit/loss.

Trends

Current period		Compared to		+/-
MRQ	-5.3%	TTM	0.9%	-6.2%
TTM	0.9%	YOY	2.2%	-1.4%
TTM	0.9%	5Y	14.6%	-13.8%
5Y	14.6%	10Y	1.5%	+13.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-5.3%	-199.6%	+194.3%
TTM	0.9%	-213.0%	+213.9%
YOY	2.2%	-279.3%	+281.5%
5Y	14.6%	-438.4%	+453.0%
10Y	1.5%	-605.5%	+607.0%

Measures how much net profit Vanda Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Vanda Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Vanda Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Vanda Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Vanda Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Vanda Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Vanda Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Vanda Pharmaceuticals Inc is -0.05. This means that Vanda Pharmaceuticals Inc earned $-0.05 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -199.6%.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Vanda Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Vanda Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Vanda Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Vanda Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Vanda Pharmaceuticals Inc = -2,400
Total revenue MRQ Vanda Pharmaceuticals Inc = 45,271
$-2,400 / $45,271 = -0.05 or -5.3%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Vanda Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
-0.4% Return on Assets means that Vanda Pharmaceuticals Inc generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Vanda Pharmaceuticals Inc:

The MRQ is -0.4%. Using its assets, the company is very inefficient in making profit. -2
The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	-0.4%	TTM	0.1%	-0.5%
TTM	0.1%	YOY	0.2%	-0.1%
TTM	0.1%	5Y	1.8%	-1.7%
5Y	1.8%	10Y	0.0%	+1.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-0.4%	-13.5%	+13.1%
TTM	0.1%	-12.9%	+13.0%
YOY	0.2%	-11.8%	+12.0%
5Y	1.8%	-14.1%	+15.9%
10Y	0.0%	-16.0%	+16.0%

Shows how efficient Vanda Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Vanda Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (-0.4%) from Vanda Pharmaceuticals Inc are higher than the Biotechnology mean (-13.5%) that means Vanda Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Vanda Pharmaceuticals Inc is -0.4%. This means the company generated $0.00 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.5%.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Vanda Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Vanda Pharmaceuticals Inc = -2,400
Total assets MRQ (balance sheet) from Vanda Pharmaceuticals Inc = 648,440
-2,400 / 648,440 = 0.00 or -0.4%

ROA is an important ratio as it will tell you how effectively Vanda Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Vanda Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
-0.4% Return on Equity means Vanda Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Vanda Pharmaceuticals Inc:

The MRQ is -0.4%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is 0.1%. Using its investors money, the company is inefficient in making profit. -1

Trends

Current period		Compared to		+/-
MRQ	-0.4%	TTM	0.1%	-0.6%
TTM	0.1%	YOY	0.3%	-0.2%
TTM	0.1%	5Y	2.2%	-2.1%
5Y	2.2%	10Y	-66.4%	+68.6%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-0.4%	-16.9%	+16.5%
TTM	0.1%	-16.1%	+16.2%
YOY	0.3%	-15.1%	+15.4%
5Y	2.2%	-19.9%	+22.1%
10Y	-66.4%	-20.9%	-45.5%

Shows how efficient Vanda Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Vanda Pharmaceuticals Inc is -0.4%. This means Vanda Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if Vanda Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Vanda Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Vanda Pharmaceuticals Inc = -2,400
Shareholders equity (balance sheet) MRQ Vanda Pharmaceuticals Inc = 544,910
-2,400 / 544,910 = 0.00 or -0.4%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Vanda Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Vanda Pharmaceuticals Inc is operating .

Measures how much profit Vanda Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of -15.7% means the company generated $-0.16 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Vanda Pharmaceuticals Inc:

The MRQ is -15.7%. The company is operating very inefficient. -2
The TTM is -8.5%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-15.7%	TTM	-8.5%	-7.1%
TTM	-8.5%	YOY	2.2%	-10.8%
TTM	-8.5%	5Y	5.9%	-14.4%
5Y	5.9%	10Y	-28.4%	+34.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-15.7%	-295.1%	+279.4%
TTM	-8.5%	-225.8%	+217.3%
YOY	2.2%	-288.4%	+290.6%
5Y	5.9%	-477.4%	+483.3%
10Y	-28.4%	-625.6%	+597.2%

Measures how efficient Vanda Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Vanda Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Vanda Pharmaceuticals Inc is -15.7%. This means that Vanda Pharmaceuticals Inc earned $-0.16 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -295.1%.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Vanda Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Vanda Pharmaceuticals Inc = -7,094
Total revenue MRQ Vanda Pharmaceuticals Inc = 45,271
$-7,094 / $45,271 = -0.16 or -15.7%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Vanda Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 1.16 means that the operating costs are $1.16 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Vanda Pharmaceuticals Inc:

The MRQ is 1.157. The company is inefficient in keeping operating costs low. -1
The TTM is 1.085. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.157	TTM	1.085	+0.071
TTM	1.085	YOY	0.978	+0.108
TTM	1.085	5Y	0.941	+0.144
5Y	0.941	10Y	1.254	-0.313

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.157	3.090	-1.933
TTM	1.085	3.264	-2.179
YOY	0.978	3.783	-2.805
5Y	0.941	5.679	-4.738
10Y	1.254	7.894	-6.640

Measures how efficient Vanda Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Vanda Pharmaceuticals Inc is 115.7%. This means that Vanda Pharmaceuticals Inc earned $1.16 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.09.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(3,460 +48,905) \ 45,271 = 1.16

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Vanda Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Vanda Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 4.94 means the company has $4.94 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Vanda Pharmaceuticals Inc:

The MRQ is 4.937. The company is very able to pay all its short-term debts. +2
The TTM is 5.764. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	4.937	TTM	5.764	-0.827
TTM	5.764	YOY	5.550	+0.214
TTM	5.764	5Y	5.839	-0.075
5Y	5.839	10Y	5.011	+0.828

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	4.937	3.914	+1.023
TTM	5.764	4.220	+1.544
YOY	5.550	5.388	+0.162
5Y	5.839	6.045	-0.206
10Y	5.011	6.406	-1.395

Measures if Vanda Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Vanda Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Vanda Pharmaceuticals Inc is 4.94. This means Vanda Pharmaceuticals Inc has $4.94 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.91.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
432,946 \ 87,697) = 4.94

The current ratio measures if Vanda Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Vanda Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Vanda Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Vanda Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Vanda Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 7.70 means the company can pay off $7.70 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Vanda Pharmaceuticals Inc:

The MRQ is 7.695. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 8.619. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	7.695	TTM	8.619	-0.923
TTM	8.619	YOY	9.384	-0.766
TTM	8.619	5Y	9.682	-1.064
5Y	9.682	10Y	8.033	+1.649

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	7.695	3.572	+4.123
TTM	8.619	3.998	+4.621
YOY	9.384	5.390	+3.994
5Y	9.682	5.969	+3.713
10Y	8.033	6.287	+1.746

Measures if Vanda Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Vanda Pharmaceuticals Inc can pay off its short term debts. This shows if Vanda Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Vanda Pharmaceuticals Inc is 7.70. This means that Vanda Pharmaceuticals Inc can pay off $7.70 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.57.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Vanda Pharmaceuticals Inc: (388,264 + 252,443 +34,155) / 87,697 = 7.70

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Vanda Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Vanda Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Vanda Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.16 means that Vanda Pharmaceuticals Inc assets are financed with 16.0% credit (debt) and the remaining percentage (100% - 16.0%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Vanda Pharmaceuticals Inc:

The MRQ is 0.160. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.160. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.160	TTM	0.160	0.000
TTM	0.160	YOY	0.168	-0.008
TTM	0.160	5Y	0.161	0.000
5Y	0.161	10Y	0.280	-0.119

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.160	0.336	-0.176
TTM	0.160	0.334	-0.174
YOY	0.168	0.269	-0.101
5Y	0.161	0.366	-0.205
10Y	0.280	0.390	-0.110

Measures how much % of Vanda Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Vanda Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Vanda Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Vanda Pharmaceuticals Inc is 0.16. This means means that Vanda Pharmaceuticals Inc is financed with 16.0% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 391.4%.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Vanda Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
103,530 \ 648,440 = 16.0% or 0.16.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Vanda Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 19.0% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Vanda Pharmaceuticals Inc:

The MRQ is 0.190. The company is very able to pay all its debts with equity. +2
The TTM is 0.191. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.190	TTM	0.191	-0.001
TTM	0.191	YOY	0.202	-0.011
TTM	0.191	5Y	0.192	-0.001
5Y	0.192	10Y	4.659	-4.467

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.190	0.382	-0.192
TTM	0.191	0.396	-0.205
YOY	0.202	0.335	-0.133
5Y	0.192	0.434	-0.242
10Y	4.659	0.465	+4.194

Measures if Vanda Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Vanda Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Vanda Pharmaceuticals Inc is 0.19. This means that Vanda Pharmaceuticals Inc can pay off $0.19 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.38.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
103,530 \ 544,910 = 0.19 or 19.0%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Vanda Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Vanda Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of -25.29 means the investor is paying $-25.29 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Vanda Pharmaceuticals Inc:

The EOD is -30.627. Based on the earnings, the company is expensive. -2
The MRQ is -25.293. Based on the earnings, the company is expensive. -2
The TTM is 130.285. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-30.627	MRQ	-25.293	-5.334
MRQ	-25.293	TTM	130.285	-155.578
TTM	130.285	YOY	23.642	+106.644
TTM	130.285	5Y	37.566	+92.720
5Y	37.566	10Y	-13.956	+51.521

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-30.627	-2.259	-28.368
MRQ	-25.293	-2.569	-22.724
TTM	130.285	-2.664	+132.949
YOY	23.642	-4.120	+27.762
5Y	37.566	-6.258	+43.824
10Y	-13.956	-6.171	-7.785

Measures how much money you pay for each share for every $1 in earnings Vanda Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Vanda Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Vanda Pharmaceuticals Inc is -25.29. This means the investor is paying $-25.29 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.57.
What is the trend?
The trend is important because it shows you how Vanda Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Vanda Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Vanda Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Vanda Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 57,532 = EPS
PE ratio MRQ = -25.29

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Vanda Pharmaceuticals Inc:

The EOD is -18.445. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -15.233. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -12.322. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-18.445	MRQ	-15.233	-3.213
MRQ	-15.233	TTM	-12.322	-2.910
TTM	-12.322	YOY	23.083	-35.405
TTM	-12.322	5Y	6.528	-18.850
5Y	6.528	10Y	11.406	-4.879

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-18.445	-2.924	-15.521
MRQ	-15.233	-3.246	-11.987
TTM	-12.322	-3.488	-8.834
YOY	23.083	-5.620	+28.703
5Y	6.528	-8.315	+14.843
10Y	11.406	-8.826	+20.232

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Vanda Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 0.45 means the investor is paying $0.45 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Vanda Pharmaceuticals Inc:

The EOD is 0.540. Based on the equity, the company is cheap. +2
The MRQ is 0.446. Based on the equity, the company is cheap. +2
The TTM is 0.584. Based on the equity, the company is cheap. +2

Trends

Current period		Compared to		+/-
EOD	0.540	MRQ	0.446	+0.094
MRQ	0.446	TTM	0.584	-0.138
TTM	0.584	YOY	1.110	-0.526
TTM	0.584	5Y	1.580	-0.996
5Y	1.580	10Y	44.560	-42.979

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	0.540	1.851	-1.311
MRQ	0.446	2.090	-1.644
TTM	0.584	2.095	-1.511
YOY	1.110	2.844	-1.734
5Y	1.580	3.466	-1.886
10Y	44.560	3.815	+40.745

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Vanda Pharmaceuticals Inc.

3.1. Institutions holding Vanda Pharmaceuticals Inc

Institutions are holding 92.207% of the shares of Vanda Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	14.506	0.0009	8346367	1587250	23.4831
2023-12-31	Renaissance Technologies Corp	6.3978	0.024	3681125	415100	12.7096
2023-12-31	Vanguard Group Inc	6.0067	0.0003	3456087	-19205	-0.5526
2023-12-31	Acadian Asset Management LLC	3.9333	0.037	2263132	512477	29.2734
2023-12-31	Nantahala Capital Management, LLC	3.5221	0.2558	2026502	1026502	102.6502
2023-12-31	Morgan Stanley - Brokerage Accounts	3.5159	0.0008	2022968	433338	27.2603
2023-12-31	Dimensional Fund Advisors, Inc.	3.4204	0.0024	1967985	-196573	-9.0814
2023-09-30	D. E. Shaw & Co LP	3.3852	0.0088	1947739	666261	51.9916
2023-12-31	Pictet Asset Manangement SA	3.3352	0.0089	1919002	181411	10.4404
2023-12-31	Assenagon Asset Management SA	2.7594	0.0178	1587717	0	0
2023-12-31	Prudential Financial Inc	2.6727	0.0098	1537780	55000	3.7092
2023-12-31	Geode Capital Management, LLC	2.1647	0.0006	1245503	66248	5.6178
2023-12-31	State Street Corporation	2.1344	0.0003	1228096	-75685	-5.805
2023-12-31	Millennium Management LLC	1.735	0.0018	998292	-1017023	-50.4647
2023-09-30	Jacobs Levy Equity Management, Inc.	1.6787	0.0247	965856	156896	19.3948
2023-12-31	Goldman Sachs Group Inc	1.6032	0.0004	922426	-750150	-44.85
2023-12-31	Two Sigma Advisers, LLC	1.5407	0.0088	886500	118200	15.3846
2023-12-31	Federated Hermes Inc	1.4217	0.0086	818027	-83482	-9.2603
2023-12-31	Two Sigma Investments LLC	1.3609	0.0076	783004	179452	29.7326
2023-09-30	Citadel Advisors Llc	1.1891	0.0006	684153	48639	7.6535
Total		68.2831	0.4199	39288261	+3304656	+8.4%

3.2. Funds holding Vanda Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-02-29	Vanguard Total Stock Mkt Idx Inv	2.9931	0.0005	1722130	0	0
2024-02-29	iShares Russell 2000 ETF	2.5009	0.0103	1438946	-235	-0.0163
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	1.5132	0.0038	870631	0	0
2023-10-13	Pictet Biopharmaceutical Mother	1.502	0.2575	864200	245226	39.6181
2023-12-31	Federated Hermes MDT SCC Institutional	1.1709	0.2403	673711	-53912	-7.4093
2023-12-31	Federated Hermes MDT Small Cap Core IS	1.1709	0.2409	673711	-53912	-7.4093
2024-02-29	BlackRock Advantage Small Cap Core Instl	1.1335	0.0831	652206	-39994	-5.7778
2023-12-31	Fidelity Small Cap Index	1.0048	0.0096	578146	0	0
2023-12-31	PGIM Quant Small Cap value Equity	0.9695	0.5576	557800	159200	39.9398
2024-02-01	iShares Russell 2000 Value ETF	0.9681	0.0176	557049	704	0.1265
2024-02-29	PGIM Quant Solutions Small-Cap Val Z	0.876	0.5695	504000	-43500	-7.9452
2024-02-29	iShares Biotechnology ETF	0.742	0.0251	426947	-1920	-0.4477
2023-12-31	Profit Inv Mgt (PIM) Profit Sm Cap Eq	0.6624	1.211	381116	62989	19.8
2023-12-31	Acadian Global Small-Cap Equity CIT Cl A	0.6437	0.4903	370349	64147	20.9492
2024-01-31	CREF Stock R1	0.6024	0.0011	346620	346620	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.5836	0.0036	335783	4200	1.2667
2024-01-31	Fidelity Extended Market Index	0.5522	0.0032	317734	0	0
2024-02-29	Dimensional US Targeted Value ETF	0.4837	0.0131	278315	0	0
2024-02-29	Schwab US Small-Cap ETF™	0.4807	0.0075	276560	0	0
2023-12-31	Vanguard Strategic Small-Cap Equity Inv	0.4322	0.0705	248672	0	0
Total		20.9858	3.8161	12074626	+689613	+5.7%

3.3. Insider Transactions

Insiders are holding 5.316% of the shares of Vanda Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price
2023-08-21	Joakim Wijkstrom	SELL	3724	5.84
2023-08-10	Stephen Ray Mitchell	SELL	6500	6.05
2023-07-28	Kevin Patrick Moran	SELL	2212	6.3
2023-06-15	Kevin Patrick Moran	SELL	16000	6.29
2023-06-13	Timothy Williams	SELL	14600	6.56

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Vanda Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.041	0.077	-47%	0.097	-58%	0.234	-83%	0.218	-81%
Book Value Per Share	-	-	9.471	9.399	+1%	8.923	+6%	8.075	+17%	5.263	+80%
Current Ratio	-	-	4.937	5.764	-14%	5.550	-11%	5.839	-15%	5.011	-1%
Debt To Asset Ratio	-	-	0.160	0.160	0%	0.168	-5%	0.161	-1%	0.280	-43%
Debt To Equity Ratio	-	-	0.190	0.191	0%	0.202	-6%	0.192	-1%	4.659	-96%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.042	0.011	-483%	0.027	-253%	0.157	-127%	0.066	-163%
Free Cash Flow Per Share	-	-	-0.069	0.054	-228%	0.136	-151%	0.176	-139%	0.049	-241%
Free Cash Flow To Equity Per Share	-	-	-0.069	0.054	-228%	0.140	-150%	0.190	-136%	0.149	-146%
Gross Profit Margin	-	-	1.000	1.000	0%	0.905	+10%	0.981	+2%	0.991	+1%
Intrinsic Value_10Y_max	-	-	7.784	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-16.584	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	0.646	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.120	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	2.043	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.697	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	3.563	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-4.729	-	-	-	-	-	-	-	-
Market Cap	294016625.000	+17%	242808250.000	315367971.520	-23%	567895125.000	-57%	683385381.804	-64%	773554781.527	-69%
Net Profit Margin	-	-	-0.053	0.009	-696%	0.022	-337%	0.146	-136%	0.015	-445%
Operating Margin	-	-	-0.157	-0.085	-46%	0.022	-804%	0.059	-366%	-0.284	+81%
Operating Ratio	-	-	1.157	1.085	+7%	0.978	+18%	0.941	+23%	1.254	-8%
Pb Ratio	0.540	+17%	0.446	0.584	-24%	1.110	-60%	1.580	-72%	44.560	-99%
Pe Ratio	-30.627	-21%	-25.293	130.285	-119%	23.642	-207%	37.566	-167%	-13.956	-45%
Price Per Share	5.110	+17%	4.220	5.480	-23%	9.870	-57%	11.877	-64%	13.444	-69%
Price To Free Cash Flow Ratio	-18.445	-21%	-15.233	-12.322	-19%	23.083	-166%	6.528	-333%	11.406	-234%
Price To Total Gains Ratio	124.824	+17%	103.084	83.390	+24%	-4.395	+104%	70.069	+47%	110.724	-7%
Quick Ratio	-	-	7.695	8.619	-11%	9.384	-18%	9.682	-21%	8.033	-4%
Return On Assets	-	-	-0.004	0.001	-477%	0.002	-253%	0.018	-120%	0.000	-1005%
Return On Equity	-	-	-0.004	0.001	-472%	0.003	-252%	0.022	-120%	-0.664	+14979%
Total Gains Per Share	-	-	0.041	0.077	-47%	0.097	-58%	0.234	-83%	0.218	-81%
Usd Book Value	-	-	544910000.000	540911750.000	+1%	513381750.000	+6%	464651450.000	+17%	302843800.000	+80%
Usd Book Value Change Per Share	-	-	0.041	0.077	-47%	0.097	-58%	0.234	-83%	0.218	-81%
Usd Book Value Per Share	-	-	9.471	9.399	+1%	8.923	+6%	8.075	+17%	5.263	+80%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.042	0.011	-483%	0.027	-253%	0.157	-127%	0.066	-163%
Usd Free Cash Flow	-	-	-3985000.000	3104500.000	-228%	7826250.000	-151%	10114650.000	-139%	2833825.000	-241%
Usd Free Cash Flow Per Share	-	-	-0.069	0.054	-228%	0.136	-151%	0.176	-139%	0.049	-241%
Usd Free Cash Flow To Equity Per Share	-	-	-0.069	0.054	-228%	0.140	-150%	0.190	-136%	0.149	-146%
Usd Market Cap	294016625.000	+17%	242808250.000	315367971.520	-23%	567895125.000	-57%	683385381.804	-64%	773554781.527	-69%
Usd Price Per Share	5.110	+17%	4.220	5.480	-23%	9.870	-57%	11.877	-64%	13.444	-69%
Usd Profit	-	-	-2400000.000	627250.000	-483%	1568750.000	-253%	9041300.000	-127%	3819400.000	-163%
Usd Revenue	-	-	45271000.000	48160000.000	-6%	63595500.000	-29%	59553000.000	-24%	46384000.000	-2%
Usd Total Gains Per Share	-	-	0.041	0.077	-47%	0.097	-58%	0.234	-83%	0.218	-81%
	EOD	+6 -2	MRQ	TTM	+10 -23	YOY	+11 -23	5Y	+11 -23	10Y	+13 -21

4.2. Fundamental Score

Let's check the fundamental score of Vanda Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-30.627
Price to Book Ratio (EOD)	Between	0-1	0.540
Net Profit Margin (MRQ)	Greater than	0	-0.053
Operating Margin (MRQ)	Greater than	0	-0.157
Quick Ratio (MRQ)	Greater than	1	7.695
Current Ratio (MRQ)	Greater than	1	4.937
Debt to Asset Ratio (MRQ)	Less than	1	0.160
Debt to Equity Ratio (MRQ)	Less than	1	0.190
Return on Equity (MRQ)	Greater than	0.15	-0.004
Return on Assets (MRQ)	Greater than	0.05	-0.004
Total			5/10 (50.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Vanda Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	63.699
Ma 20	Greater than	Ma 50	4.371
Ma 50	Greater than	Ma 100	4.236
Ma 100	Greater than	Ma 200	4.054
Open	Greater than	Close	4.940
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Net Income		6,861	-3,609	3,252	-1,732	1,520	-1,383	137	-2,537	-2,400
Net Income from Continuing Operations		6,861	-3,609	3,252	-1,732	1,520	-1,383	137	-2,537	-2,400

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	648,440
Total Liabilities	103,530
Total Stockholder Equity	544,910

	As reported
Total Liabilities	103,530
Total Stockholder Equity	+ 544,910
Total Assets	= 648,440

Assets

Total Assets	648,440
Total Current Assets	432,946
Long-term Assets	215,494

Total Current Assets

Total Current Assets (as reported)	432,946
Cash And Cash Equivalents	135,821
Short-term Investments	252,443
Net Receivables	34,155
Inventory	1,357
Other Current Assets	9,170
Total Current Assets (calculated)	432,946
+/-	0

Long-term Assets

Long-term Assets (as reported)	215,494
Property Plant Equipment	9,140
Intangible Assets	121,369
Long-term Assets Other	9,516
Long-term Assets (calculated)	140,025
+/-	75,469

Liabilities & Shareholders' Equity

Total Current Liabilities	87,697
Long-term Liabilities	15,833
Total Stockholder Equity	544,910

Total Current Liabilities

Total Current Liabilities (as reported)	87,697
Short-term Debt	2,398
Accounts payable	7,145
Other Current Liabilities	78,154
Total Current Liabilities (calculated)	87,697
+/-	0

Long-term Liabilities

Long-term Liabilities (as reported)	15,833
Capital Lease Obligations Min Short Term Debt	7,006
Long-term Liabilities Other	8,827
Long-term Liabilities (calculated)	15,833
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	544,910
Common Stock	58
Retained Earnings	-155,392
Accumulated Other Comprehensive Income	-30
Other Stockholders Equity	700,274
Total Stockholder Equity (calculated)	544,910
+/-	0

Other

Capital Stock	58
Cash and Short Term Investments	388,264
Common Stock Shares Outstanding	57,532
Liabilities and Stockholders Equity	648,440
Net Debt	-126,417
Net Invested Capital	544,910
Net Working Capital	345,249
Property Plant and Equipment Gross	20,321
Short Long Term Debt Total	9,404

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

> Total Assets

17,752
0
0
0
35,753
25,188
64,768
47,282
36,260
134,168
125,318
114,886
96,861
80,396
70,258
57,072
49,934
45,829
45,144
38,309
225,714
225,920
222,887
217,354
213,101
209,333
203,438
195,738
182,618
172,599
160,838
149,808
135,448
125,139
116,954
155,090
143,349
120,982
86,172
79,175
171,704
213,640
223,693
220,544
213,050
206,740
202,038
208,443
210,374
204,720
210,671
205,706
205,425
317,315
302,926
311,937
332,130
351,166
372,483
474,449
483,748
488,525
506,631
515,905
533,456
543,191
567,645
579,767
593,792
603,558
609,102
621,788
634,247
644,532
641,682
641,605
648,440

648,440

641,605

641,682

644,532

634,247

621,788

609,102

603,558

593,792

579,767

567,645

543,191

533,456

515,905

506,631

488,525

483,748

474,449

372,483

351,166

332,130

311,937

302,926

317,315

205,425

205,706

210,671

204,720

210,374

208,443

202,038

206,740

213,050

220,544

223,693

213,640

171,704

79,175

86,172

120,982

143,349

155,090

116,954

125,139

135,448

149,808

160,838

172,599

182,618

195,738

203,438

209,333

213,101

217,354

222,887

225,920

225,714

38,309

45,144

45,829

49,934

57,072

70,258

80,396

96,861

114,886

125,318

134,168

36,260

47,282

64,768

25,188

35,753

17,752

> Total Current Assets

0
0
0
0
33,372
22,590
62,258
44,824
33,820
128,758
122,968
108,868
86,955
72,220
65,099
54,606
47,746
43,763
31,424
25,074
212,950
213,662
211,086
206,010
200,573
197,251
191,525
164,719
153,501
161,349
149,989
139,853
125,968
116,112
108,355
147,070
135,614
105,517
71,220
64,838
141,730
162,167
174,373
173,877
166,547
162,449
160,376
170,408
174,175
168,562
174,609
169,719
169,857
282,435
269,102
278,807
299,132
306,498
315,802
280,010
354,136
360,746
380,861
389,534
409,145
421,224
446,652
461,808
478,301
492,268
496,895
507,106
519,292
533,707
533,504
536,572
432,946

432,946

536,572

533,504

533,707

519,292

507,106

496,895

492,268

478,301

461,808

446,652

421,224

409,145

389,534

380,861

360,746

354,136

280,010

315,802

306,498

299,132

278,807

269,102

282,435

169,857

169,719

174,609

168,562

174,175

170,408

160,376

162,449

166,547

173,877

174,373

162,167

141,730

64,838

71,220

105,517

135,614

147,070

108,355

116,112

125,968

139,853

149,989

161,349

153,501

164,719

191,525

197,251

200,573

206,010

211,086

213,662

212,950

25,074

31,424

43,763

47,746

54,606

65,099

72,220

86,955

108,868

122,968

128,758

33,820

44,824

62,258

22,590

33,372

Cash And Cash Equivalents

16,259
0
0
0
21,013
12,520
46,440
31,900
30,929
64,221
47,631
59,954
41,930
56,015
56,504
41,439
39,079
33,833
24,014
17,418
205,295
169,946
145,651
102,468
42,559
52,520
50,386
60,326
87,923
108,094
94,388
104,515
88,772
109,931
103,633
142,172
64,764
43,260
16,994
15,308
60,901
32,809
48,337
46,786
50,843
38,740
23,194
32,765
40,426
20,111
14,232
22,586
33,627
155,293
60,891
60,778
61,005
34,379
46,543
39,208
45,072
64,950
95,305
56,973
61,031
72,132
57,242
50,522
52,071
66,927
58,226
49,397
135,029
354,171
150,031
183,186
135,821

135,821

183,186

150,031

354,171

135,029

49,397

58,226

66,927

52,071

50,522

57,242

72,132

61,031

56,973

95,305

64,950

45,072

39,208

46,543

34,379

61,005

60,778

60,891

155,293

33,627

22,586

14,232

20,111

40,426

32,765

23,194

38,740

50,843

46,786

48,337

32,809

60,901

15,308

16,994

43,260

64,764

142,172

103,633

109,931

88,772

104,515

94,388

108,094

87,923

60,326

50,386

52,520

42,559

102,468

145,651

169,946

205,295

17,418

24,014

33,833

39,079

41,439

56,504

56,015

41,930

59,954

47,631

64,221

30,929

31,900

46,440

12,520

21,013

16,259

Short-term Investments

0
0
0
0
10,141
7,599
13,731
11,097
942
62,698
72,031
45,474
43,244
15,028
6,565
10,225
7,379
8,811
5,009
3,265
0
32,478
61,467
99,592
155,478
142,035
138,013
101,122
60,961
49,156
50,313
29,889
31,631
1,001
430
530
65,586
57,142
46,591
40,781
68,921
101,520
98,300
97,529
92,337
99,590
112,795
109,814
100,914
117,645
122,886
117,295
109,786
93,541
170,325
179,801
196,355
233,457
233,618
198,577
267,057
247,376
244,544
291,575
306,709
306,030
339,251
355,446
380,742
368,249
382,632
405,394
331,830
147,325
339,320
306,672
252,443

252,443

306,672

339,320

147,325

331,830

405,394

382,632

368,249

380,742

355,446

339,251

306,030

306,709

291,575

244,544

247,376

267,057

198,577

233,618

233,457

196,355

179,801

170,325

93,541

109,786

117,295

122,886

117,645

100,914

109,814

112,795

99,590

92,337

97,529

98,300

101,520

68,921

40,781

46,591

57,142

65,586

530

430

1,001

31,631

29,889

50,313

49,156

60,961

101,122

138,013

142,035

155,478

99,592

61,467

32,478

3,265

5,009

8,811

7,379

10,225

6,565

15,028

43,244

45,474

72,031

62,698

942

11,097

13,731

7,599

10,141

Net Receivables

0
0
0
0
0
0
0
0
108
18
15
4
5
80
0
11
0
0
0
0
3,164
6,097
655
494
511
895
752
1,216
1,618
1,535
1,700
1,535
1,168
1,462
1,701
1,956
2,031
1,790
2,376
3,696
3,654
20,120
15,818
15,789
16,331
16,679
14,030
15,928
20,268
17,751
21,024
18,179
17,601
23,314
24,855
25,259
28,780
26,346
23,890
26,824
26,367
29,272
24,587
28,033
30,036
31,474
37,090
41,496
32,467
30,497
28,805
29,352
33,512
24,513
33,621
29,272
34,155

34,155

29,272

33,621

24,513

33,512

29,352

28,805

30,497

32,467

41,496

37,090

31,474

30,036

28,033

24,587

29,272

26,367

26,824

23,890

26,346

28,780

25,259

24,855

23,314

17,601

18,179

21,024

17,751

20,268

15,928

14,030

16,679

16,331

15,789

15,818

20,120

3,654

3,696

2,376

1,790

2,031

1,956

1,701

1,462

1,168

1,535

1,700

1,535

1,618

1,216

752

895

511

494

655

6,097

3,164

108

Inventory

0
0
0
0
0
0
0
0
924
575
2,130
2,228
718
515
0
2,803
0
0
1,272
1,758
2,399
1,480
0
0
0
0
0
0
0
0
165
161
57
21
28
530
530
192
1,093
1,016
5,170
4,923
4,962
3,797
1,294
938
927
865
779
816
742
921
840
1,011
1,193
887
994
1,112
1,057
1,019
1,140
1,320
1,384
1,322
1,280
1,361
1,055
902
1,025
1,290
1,496
1,590
1,194
1,105
1,080
1,006
1,357

1,357

1,006

1,080

1,105

1,194

1,590

1,496

1,290

1,025

902

1,055

1,361

1,280

1,322

1,384

1,320

1,140

1,019

1,057

1,112

994

887

1,193

1,011

840

921

742

816

779

865

927

938

1,294

3,797

4,962

4,923

5,170

1,016

1,093

192

530

161

165

1,480

2,399

1,758

1,272

2,803

515

718

2,228

2,130

575

924

> Long-term Assets

0
0
0
0
2,381
2,599
2,511
2,459
2,440
5,410
2,351
6,018
9,905
8,176
5,159
2,466
2,188
2,066
13,719
13,235
12,764
12,258
11,801
11,345
12,528
12,082
11,913
31,019
29,117
11,250
10,849
9,955
9,480
9,027
8,599
8,020
7,735
15,465
14,952
14,337
29,974
51,473
49,320
46,667
46,503
44,291
41,662
38,035
36,199
36,158
36,062
35,987
35,568
34,880
33,824
33,130
32,998
44,668
56,681
194,439
129,612
127,779
125,770
126,371
124,311
121,967
120,993
117,959
115,491
111,290
112,207
114,682
114,955
110,825
108,178
105,033
215,494

215,494

105,033

108,178

110,825

114,955

114,682

112,207

111,290

115,491

117,959

120,993

121,967

124,311

126,371

125,770

127,779

129,612

194,439

56,681

44,668

32,998

33,130

33,824

34,880

35,568

35,987

36,062

36,158

36,199

38,035

41,662

44,291

46,503

46,667

49,320

51,473

29,974

14,337

14,952

15,465

7,735

8,020

8,599

9,027

9,480

9,955

10,849

11,250

29,117

31,019

11,913

12,082

12,528

11,345

11,801

12,258

12,764

13,235

13,719

2,066

2,188

2,466

5,159

8,176

9,905

6,018

2,351

5,410

2,440

2,459

2,511

2,599

2,381

Property Plant Equipment

1,252
0
0
0
1,111
1,328
1,900
1,848
1,860
1,830
1,771
1,445
1,346
1,602
2,021
1,886
1,758
1,635
1,518
1,411
1,316
1,179
1,095
1,015
937
860
963
851
964
2,478
2,533
2,446
2,348
2,264
2,208
2,106
2,198
2,208
2,312
2,233
2,437
3,080
3,869
4,159
4,570
4,351
4,246
4,731
5,015
5,461
5,709
5,448
5,306
5,105
4,800
4,579
4,417
16,288
15,958
15,592
15,044
14,752
14,345
14,227
14,595
14,034
13,529
12,898
12,385
11,862
11,349
10,856
10,973
10,430
9,946
9,556
9,140

9,140

9,556

9,946

10,430

10,973

10,856

11,349

11,862

12,385

12,898

13,529

14,034

14,595

14,227

14,345

14,752

15,044

15,592

15,958

16,288

4,417

4,579

4,800

5,105

5,306

5,448

5,709

5,461

5,015

4,731

4,246

4,351

4,570

4,159

3,869

3,080

2,437

2,233

2,312

2,208

2,198

2,106

2,208

2,264

2,348

2,446

2,533

2,478

964

851

963

860

937

1,015

1,095

1,179

1,316

1,411

1,518

1,635

1,758

1,886

2,021

1,602

1,346

1,445

1,771

1,830

1,860

1,848

1,900

1,328

1,111

1,252

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,011
19,012
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,517
61,827
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

61,827

12,517

19,012

19,011

Intangible Assets

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,771
11,394
11,017
10,648
10,276
9,899
9,522
9,153
8,781
8,404
8,027
7,658
7,286
6,909
6,532
6,163
5,791
5,414
5,037
12,472
11,855
11,319
26,724
47,580
44,638
41,695
38,752
35,809
32,867
29,924
27,819
27,365
26,933
26,501
26,069
25,717
25,319
24,922
24,542
24,162
23,783
23,407
23,037
22,667
22,298
21,929
21,559
21,189
20,820
20,450
20,081
19,702
19,323
18,944
18,565
18,186
17,808
17,428
121,369

121,369

17,428

17,808

18,186

18,565

18,944

19,323

19,702

20,081

20,450

20,820

21,189

21,559

21,929

22,298

22,667

23,037

23,407

23,783

24,162

24,542

24,922

25,319

25,717

26,069

26,501

26,933

27,365

27,819

29,924

32,867

35,809

38,752

41,695

44,638

47,580

26,724

11,319

11,855

12,472

5,037

5,414

5,791

6,163

6,532

6,909

7,286

7,658

8,027

8,404

8,781

9,153

9,522

9,899

10,276

10,648

11,017

11,394

11,771

Long-term Assets Other

0
0
0
0
1,270
1,270
610
610
580
-2,996,601
580
580
580
580
580
580
430
430
430
430
430
430
430
430
430
430
530
1,114
1,114
1,114
1,030
600
600
600
600
500
500
785
785
785
813
813
813
813
3,181
4,131
4,549
3,380
3,365
3,332
3,420
4,038
4,193
4,058
3,705
3,629
4,039
4,218
4,423
4,541
3,851
3,719
3,569
6,357
6,641
6,389
8,003
8,506
8,147
8,928
8,848
9,884
10,909
9,993
9,479
9,808
9,516

9,516

9,808

9,479

9,993

10,909

9,884

8,848

8,928

8,147

8,506

8,003

6,389

6,641

6,357

3,569

3,719

3,851

4,541

4,423

4,218

4,039

3,629

3,705

4,058

4,193

4,038

3,420

3,332

3,365

3,380

4,549

4,131

3,181

813

785

500

600

1,030

1,114

530

430

580

-2,996,601

580

610

1,270

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,639
1,639
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89,072
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

89,072

1,639

> Total Liabilities

1,808
0
0
0
5,088
11,126
17,201
10,331
9,503
7,363
9,286
15,595
13,132
10,740
10,173
4,478
3,914
3,984
11,837
8,898
202,683
199,289
192,837
183,195
175,370
169,765
163,900
158,056
149,144
145,679
140,754
134,456
125,543
118,658
111,928
105,088
99,225
99,999
85,287
78,112
10,887
61,167
73,946
74,607
80,023
83,728
80,424
79,278
79,044
76,578
79,253
75,237
74,038
76,171
51,655
50,520
56,708
72,761
75,789
73,542
72,803
72,139
75,047
75,333
80,190
75,564
86,425
86,446
88,864
101,435
100,553
106,131
107,049
108,793
101,784
98,505
103,530

103,530

98,505

101,784

108,793

107,049

106,131

100,553

101,435

88,864

86,446

86,425

75,564

80,190

75,333

75,047

72,139

72,803

73,542

75,789

72,761

56,708

50,520

51,655

76,171

74,038

75,237

79,253

76,578

79,044

79,278

80,424

83,728

80,023

74,607

73,946

61,167

10,887

78,112

85,287

99,999

99,225

105,088

111,928

118,658

125,543

134,456

140,754

145,679

149,144

158,056

163,900

169,765

175,370

183,195

192,837

199,289

202,683

8,898

11,837

3,984

3,914

4,478

10,173

10,740

13,132

15,595

9,286

7,363

9,503

10,331

17,201

11,126

5,088

1,808

> Total Current Liabilities

1,623
0
0
0
5,064
10,995
17,025
10,088
9,106
6,914
9,032
15,315
12,778
10,318
9,682
3,981
3,411
3,481
11,332
8,392
31,534
34,750
34,980
32,095
31,027
32,036
32,860
33,640
31,619
32,662
34,386
34,632
32,263
31,973
31,935
31,905
32,851
45,404
38,294
38,845
7,786
31,789
45,193
45,889
51,317
55,040
51,761
50,681
50,320
72,968
75,436
71,536
70,363
71,955
46,881
46,242
53,015
59,275
62,576
59,996
59,505
59,222
61,592
61,359
65,936
61,784
71,989
71,997
74,419
90,742
88,400
92,623
91,436
93,794
87,397
84,837
87,697

87,697

84,837

87,397

93,794

91,436

92,623

88,400

90,742

74,419

71,997

71,989

61,784

65,936

61,359

61,592

59,222

59,505

59,996

62,576

59,275

53,015

46,242

46,881

71,955

70,363

71,536

75,436

72,968

50,320

50,681

51,761

55,040

51,317

45,889

45,193

31,789

7,786

38,845

38,294

45,404

32,851

31,905

31,935

31,973

32,263

34,632

34,386

32,662

31,619

33,640

32,860

32,036

31,027

32,095

34,980

34,750

31,534

8,392

11,332

3,481

3,411

3,981

9,682

10,318

12,778

15,315

9,032

6,914

9,106

10,088

17,025

10,995

5,064

1,623

Short-term Debt

0
0
0
0
142
96
49
0
-129,950
-142,411
-134,939
0
0
0
0
0
0
0
0
0
0
5,740
5,764
3,235
2,266
2,272
2,221
2,108
0
0
0
0
0
0
0
0
0
0
0
0
6,749
0
0
0
0
0
25,000
25,000
0
25,000
25,000
27,000
27,000
27,000
0
0
0
2,249
2,257
2,123
2,147
2,101
2,181
1,978
2,117
2,126
2,142
2,295
2,311
2,297
2,245
2,199
2,328
2,346
2,366
2,374
2,398

2,398

2,374

2,366

2,346

2,328

2,199

2,245

2,297

2,311

2,295

2,142

2,126

2,117

1,978

2,181

2,101

2,147

2,123

2,257

2,249

27,000

25,000

6,749

2,108

2,221

2,272

2,266

3,235

5,764

5,740

-134,939

-142,411

-129,950

142

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,000
25,000
0
25,000
25,000
27,000
27,000
27,000
0
0
0
2,249
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

2,249

27,000

25,000

Accounts payable

719
0
0
0
2,255
3,378
5,063
2,112
2,783
2,010
2,600
3,446
2,988
1,826
5,826
899
512
1,415
6,917
6,346
2,424
868
1,020
295
648
834
1,337
1,333
996
780
1,689
1,090
287
1,113
1,167
369
661
953
248
547
835
1,490
1,631
45,889
15,767
22,664
17,933
17,572
16,196
18,025
19,126
18,921
20,335
17,242
18,562
19,046
21,584
27,423
29,307
26,992
27,590
26,045
28,398
29,086
31,509
26,105
2,117
1,299
925
14,327
16,412
13,433
12,690
3,800
2,170
3,488
7,145

7,145

3,488

2,170

3,800

12,690

13,433

16,412

14,327

925

1,299

2,117

26,105

31,509

29,086

28,398

26,045

27,590

26,992

29,307

27,423

21,584

19,046

18,562

17,242

20,335

18,921

19,126

18,025

16,196

17,572

17,933

22,664

15,767

45,889

1,631

1,490

835

547

248

953

661

369

1,167

1,113

287

1,090

1,689

780

996

1,333

1,337

834

648

295

1,020

868

2,424

6,346

6,917

1,415

512

899

5,826

1,826

2,988

3,446

2,600

2,010

2,783

2,112

5,063

3,378

2,255

719

Other Current Liabilities

693
0
0
0
2,536
7,387
11,777
-128,275
6,323
4,904
141
11,868
9,790
8,492
3,856
3,082
2,898
2,065
4,415
2,046
2,321
1,353
1,408
1,776
1,324
2,141
2,513
3,410
3,381
5,093
5,908
6,753
5,187
4,071
3,979
4,747
5,401
13,392
6,987
7,066
28
30,299
43,562
45,889
35,550
32,376
33,828
50,681
34,124
72,968
75,436
71,536
50,028
71,955
46,881
46,242
53,015
57,026
60,319
57,873
57,358
57,121
59,411
59,381
32,310
59,658
67,730
68,403
71,183
74,118
69,743
76,991
76,418
87,648
87,397
84,837
78,154

78,154

84,837

87,397

87,648

76,418

76,991

69,743

74,118

71,183

68,403

67,730

59,658

32,310

59,381

59,411

57,121

57,358

57,873

60,319

57,026

53,015

46,242

46,881

71,955

50,028

71,536

75,436

72,968

34,124

50,681

33,828

32,376

35,550

45,889

43,562

30,299

7,066

6,987

13,392

5,401

4,747

3,979

4,071

5,187

6,753

5,908

5,093

3,381

3,410

2,513

2,141

1,324

1,776

1,408

1,353

2,321

2,046

4,415

2,065

2,898

3,082

3,856

8,492

9,790

11,868

141

4,904

6,323

-128,275

11,777

7,387

2,536

693

> Long-term Liabilities

0
0
0
0
24
130
175
242
397
448
254
281
354
422
491
497
503
504
505
506
171,149
164,539
157,856
151,100
144,343
137,729
131,040
124,416
117,525
113,017
106,368
99,824
93,280
86,685
79,993
73,183
66,374
54,595
46,993
39,267
3,101
29,378
28,753
28,718
28,706
28,688
28,663
28,597
28,724
3,610
3,817
3,701
3,675
4,216
4,774
4,278
3,693
13,486
13,213
13,546
13,298
12,917
13,455
13,974
14,254
13,780
14,436
14,449
14,445
10,693
12,153
13,508
15,613
14,999
14,387
13,668
15,833

15,833

13,668

14,387

14,999

15,613

13,508

12,153

10,693

14,445

14,449

14,436

13,780

14,254

13,974

13,455

12,917

13,298

13,546

13,213

13,486

3,693

4,278

4,774

4,216

3,675

3,701

3,817

3,610

28,724

28,597

28,663

28,688

28,706

28,718

28,753

29,378

3,101

39,267

46,993

54,595

66,374

73,183

79,993

86,685

93,280

99,824

106,368

113,017

117,525

124,416

131,040

137,729

144,343

151,100

157,856

164,539

171,149

506

505

504

503

497

491

422

354

281

254

448

397

242

175

130

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,000
25,000
25,000
25,000
25,000
25,000
25,000
25,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

25,000

Capital Lease Obligations Min Short Term Debt

0
0
0
0
-142
-96
-49
0
129,950
142,411
134,939
0
0
0
0
0
0
0
0
0
0
-5,740
-5,764
-3,235
-2,266
-2,272
-2,221
-2,108
0
0
0
0
0
0
0
0
0
0
0
0
-6,749
0
0
0
0
0
-25,000
-25,000
0
-25,000
-25,000
-27,000
-27,000
-27,000
0
0
0
13,324
12,992
12,793
12,455
12,139
11,720
11,559
11,497
11,125
8,598
10,457
10,055
9,660
9,286
8,903
8,813
8,387
5,576
5,098
7,006

7,006

5,098

5,576

8,387

8,813

8,903

9,286

9,660

10,055

10,457

8,598

11,125

11,497

11,559

11,720

12,139

12,455

12,793

12,992

13,324

-27,000

-25,000

-6,749

-2,108

-2,221

-2,272

-2,266

-3,235

-5,764

-5,740

134,939

142,411

129,950

-49

-96

-142

Deferred Long Term Asset Charges

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,639
1,639
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
89,072
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

89,072

1,639

Long-term Liabilities Other

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
278
0
0
0
0
0
0
0
0
140
113
0
4,378
3,753
3,718
3,706
3,688
3,663
3,597
3,724
3,610
3,817
3,701
3,675
4,216
4,774
4,278
3,693
13,486
13,213
13,546
13,298
12,917
13,455
13,974
14,254
13,780
3,696
14,449
14,445
10,693
12,153
13,508
15,613
14,999
6,445
6,196
8,827

8,827

6,196

6,445

14,999

15,613

13,508

12,153

10,693

14,445

14,449

3,696

13,780

14,254

13,974

13,455

12,917

13,298

13,546

13,213

13,486

3,693

4,278

4,774

4,216

3,675

3,701

3,817

3,610

3,724

3,597

3,663

3,688

3,706

3,718

3,753

4,378

113

140

278

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
131,040
124,416
117,525
112,739
106,368
99,824
90,275
86,685
79,993
73,183
66,374
54,595
46,853
39,154
3,101
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

3,101

39,154

46,853

54,595

66,374

73,183

79,993

86,685

90,275

99,824

106,368

112,739

117,525

124,416

131,040

> Total Stockholder Equity

15,944
0
0
0
30,665
14,063
47,568
36,952
26,757
126,806
116,033
99,290
83,729
69,656
60,085
52,594
46,020
41,844
33,307
29,411
23,031
26,631
30,050
34,159
37,731
39,568
39,538
37,682
33,474
26,920
20,084
15,352
9,905
6,481
5,026
50,002
44,124
20,983
885
1,063
160,817
152,473
149,747
145,937
133,027
123,012
121,614
129,165
131,330
128,142
131,418
130,469
131,387
241,144
251,271
261,417
275,422
278,405
296,694
400,907
410,945
416,386
431,584
440,572
453,266
467,627
481,220
493,321
504,928
502,123
508,549
515,657
527,198
535,739
539,898
543,100
544,910

544,910

543,100

539,898

535,739

527,198

515,657

508,549

502,123

504,928

493,321

481,220

467,627

453,266

440,572

431,584

416,386

410,945

400,907

296,694

278,405

275,422

261,417

251,271

241,144

131,387

130,469

131,418

128,142

131,330

129,165

121,614

123,012

133,027

145,937

149,747

152,473

160,817

1,063

885

20,983

44,124

50,002

5,026

6,481

9,905

15,352

20,084

26,920

33,474

37,682

39,538

39,568

37,731

34,159

30,050

26,631

23,031

29,411

33,307

41,844

46,020

52,594

60,085

69,656

83,729

99,290

116,033

126,806

26,757

36,952

47,568

14,063

30,665

15,944

Common Stock

0
0
0
0
16
0
22
22
22
27
27
27
27
27
27
27
27
27
27
27
28
28
28
28
28
28
28
28
28
28
28
28
28
28
28
33
33
34
34
34
41
42
42
43
43
43
43
44
44
45
45
45
45
52
52
52
52
53
53
53
54
54
55
55
55
56
56
56
56
56
57
57
57
57
57
58
58

Retained Earnings Total Equity

-153,129

-154,649

-157,901

-164,762

-168,032

-170,606

-164,176

-171,254

-179,025

-188,678

-197,328

-205,518

-211,465

-220,179

-220,665

-224,881

-325,304

-336,830

-336,218

-346,578

-353,749

-358,360

-361,426

-359,588

-355,038

-353,504

-345,859

-345,255

-344,825

-340,207

-327,849

-313,051

-303,591

-298,205

-287,984

-357,703

-356,278

-334,703

-311,362

-303,739

-298,359

-295,280

-291,107

-284,738

-279,412

-271,405

-263,443

-257,920

-254,846

Accumulated Other Comprehensive Income

0
0
0
0
-18,784
-18
-16
-15
-3
-17
-8
13
12
30
-15
-242
-1,917
-1
0
0
-2,346
17
56
52
2
99
85
44
21
27
5
23
10
0
0
0
21
8
10
4
16
27
27
37
39
92
124
142
58
50
11
73
-34
-28
79
70
1
135
386
211
249
781
596
379
239
192
103
111
-175
-1,328
-1,431
-1,485
-1,193
-255
-865
-967
-30

-30

-967

-865

-255

-1,193

-1,485

-1,431

-1,328

-175

111

103

192

239

379

596

781

249

211

386

135

-28

-34

142

124

-2,346

-1

-1,917

-242

-15

-8

-17

-3

-15

-16

-18

-18,784

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
294,271
295,530
296,868
298,270
299,463
300,039
300,974
301,733
303,357
353,708
355,432
355,644
357,119
358,728
448,744
450,609
453,269
458,908
460,794
463,084
466,272
474,234
477,087
481,551
486,400
489,939
492,802
599,480
604,889
607,873
611,587
615,047
621,559
625,524
631,307
635,730
642,398
645,656
650,300
656,057
660,086
664,408
669,223
674,001
677,955
681,847
686,235
690,586
693,835
0
0

693,835

690,586

686,235

681,847

677,955

674,001

669,223

664,408

660,086

656,057

650,300

645,656

642,398

635,730

631,307

625,524

621,559

615,047

611,587

607,873

604,889

599,480

492,802

489,939

486,400

481,551

477,087

474,234

466,272

463,084

460,794

458,908

453,269

450,609

448,744

358,728

357,119

355,644

355,432

353,708

303,357

301,733

300,974

300,039

299,463

298,270

296,868

295,530

294,271

Treasury Stock

Other Stockholders Equity

0
0
0
0
85,762
6,737
123,387
124,894
126,579
242,030
247,232
252,412
257,600
262,706
266,675
270,280
272,885
273,297
277,150
280,980
283,837
286,890
288,991
289,920
291,342
292,946
294,271
295,530
296,868
298,270
299,463
300,039
300,974
301,733
303,357
353,708
355,432
355,644
357,119
358,728
448,744
450,609
453,269
458,908
460,794
463,084
466,272
474,234
477,087
481,551
486,400
489,939
492,802
599,480
604,889
607,873
611,587
615,047
621,559
625,524
631,307
635,730
642,398
645,656
452,972
656,057
660,086
664,408
669,223
674,001
677,955
681,847
686,235
690,586
693,835
697,001
700,274

700,274

697,001

693,835

690,586

686,235

681,847

677,955

674,001

669,223

664,408

660,086

656,057

452,972

645,656

642,398

635,730

631,307

625,524

621,559

615,047

611,587

607,873

604,889

599,480

492,802

489,939

486,400

481,551

477,087

474,234

466,272

463,084

460,794

458,908

453,269

450,609

448,744

358,728

357,119

355,644

355,432

353,708

303,357

301,733

300,974

300,039

299,463

298,270

296,868

295,530

294,271

292,946

291,342

289,920

288,991

286,890

283,837

280,980

277,150

273,297

272,885

270,280

266,675

262,706

257,600

252,412

247,232

242,030

126,579

124,894

123,387

6,737

85,762

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Accounts Payable	9,554	12,690	925	5,817	5,904	21,584	20,335	16,196	15,767	835	661	287	996	649	2,424	512	2,988	2,783	2,255	719
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-30	-1,193	-175	239	249	1	-34	58	39	16	21	10	21	2	-2,346	-1,917	12	-3	-18,784	-3
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	9,404	11,141	12,366	13,614	14,602	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	58	57	56	55	54	52	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	686,235	669,223	650,300	631,307	611,587	492,802	477,087	460,794	448,744	355,432	0	296,868	0	0	0	0	0	0	0
Cash	135,821	135,029	52,071	61,031	45,072	61,005	33,627	40,426	50,843	60,901	64,764	88,772	87,923	42,559	205,295	39,079	41,930	30,929	21,013	16,260
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	388,264	466,859	432,813	367,740	312,129	257,360	143,413	141,340	143,180	129,822	130,350	120,403	148,884	198,037	205,295	46,458	85,173	31,871	31,154	16,260
Common Stock	58	57	56	55	54	52	45	44	43	41	33	28	28	28	28	27	27	22	16	0
Common Stock Shares Outstanding	57,558	56,983	56,922	55,191	54,847	53,045	44,735	43,449	42,250	36,687	30,351	28,228	28,107	28,535	27,015	26,650	26,360	16,002	21,907	469,970
Common Stock Total Equity	0	57	56	55	54	52	45	44	43	41	33	28	28	28	28	27	27	22	16	0
Current Deferred Revenue	0	0	0	-5,817	-5,904	0	0	0	0	174	26,789	26,789	27,242	26,789	26,789	0	0	129,950	130	689
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	3,101	66,374	90,275	117,525	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	121,369	18,565	20,081	21,559	23,037	24,542	26,069	27,819	38,752	26,724	5,037	6,532	8,027	9,522	11,017	0	0	0	0	0
Inventory	1,357	1,194	1,025	1,280	1,140	994	840	779	1,294	5,170	530	57	0	1,639	2,399	0	718	924	0	0
Liabilities And Stockholders Equity	648,440	634,247	593,792	533,456	483,748	332,130	205,425	210,374	213,050	171,704	143,349	135,448	182,618	213,101	225,714	49,934	96,861	36,260	35,753	17,752
Long Term Debt	0	0	0	0	0	0	0	25,000	25,000	0	0	0	0	0	0	0	0	0	0	155
Long Term Debt Total	0	0	0	0	0	0	0	25,000	25,000	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	19,012	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	-126,417	-123,888	-42,016	-47,417	-32,617	-61,005	-33,627	-40,426	-50,843	-60,901	-64,764	-88,772	-87,923	-42,559	-205,295	-39,079	-41,930	-30,929	-20,870	-15,893
Net Invested Capital	544,910	527,198	504,928	453,266	410,945	275,422	131,387	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	34,155	33,512	32,467	30,036	26,367	28,780	17,601	20,268	16,331	3,654	2,031	1,168	1,618	511	3,164	0	5	108	0	0
Net Tangible Assets	0	508,633	484,847	431,707	387,908	250,880	105,318	103,511	94,275	134,093	39,087	0	25,447	0	0	0	0	0	0	0
Net Working Capital	345,249	427,856	403,882	343,209	294,631	246,117	99,494	123,855	115,230	133,944	102,763	93,705	121,882	171,184	181,416	44,335	74,178	24,714	28,308	14,828
Non Current Assets Total	215,494	114,955	115,491	124,311	129,612	32,998	35,568	36,199	46,503	29,974	7,735	9,480	29,117	10,889	12,764	2,188	9,905	2,440	2,381	1,302
Non Current Liabilities Other	8,827	15,613	14,445	14,254	13,298	3,693	3,675	3,724	3,706	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	15,833	15,613	14,445	14,254	13,298	3,693	3,675	28,724	28,706	3,101	66,374	93,280	117,525	144,343	171,149	503	354	397	24	186
Non Currrent Assets Other	9,516	10,909	7,628	6,116	3,273	4,039	4,193	3,365	3,181	813	500	600	1,114	-1,209	430	430	8,560	580	1,270	50
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	85,417	83,025	88,157	91,531	4,039	4,193	3,365	3,181	813	500	600	1,114	2,069	430	430	580	580	1,270	50
Other Current Assets	9,170	17,727	11,996	10,089	14,500	11,998	8,003	11,788	5,742	3,084	2,703	3,910	2,999	2,025	2,093	1,287	1,059	918	2,218	191
Other Current Liab	75,745	76,418	71,183	63,819	57,358	53,015	50,028	34,124	35,550	6,777	5,401	5,187	3,381	3,590	2,321	2,898	9,790	6,323	2,536	693
Other Liab	0	6,800	4,390	2,757	843	3,693	3,675	28,724	28,706	3,101	66,374	93,280	117,525	144,343	171,149	503	354	397	24	30
Other Stockholder Equity	700,274	686,235	669,223	650,300	631,307	611,587	492,802	477,087	460,794	448,744	355,432	300,974	296,868	291,342	283,837	270,968	257,600	126,579	85,762	165
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	61,795	28,309
Property Plant And Equipment Gross	20,321	10,973	12,385	4,136	15,044	4,417	5,306	5,015	4,570	2,437	2,198	2,348	964	937	1,316	1,758	1,346	1,860	1,111	1,252
Property Plant And Equipment Net	9,140	10,973	12,385	14,595	15,044	4,417	5,306	5,015	4,570	2,437	2,198	2,348	964	937	1,316	1,758	1,346	1,860	1,111	1,252
Property Plant Equipment	0	2,573	12,385	4,136	3,864	4,417	5,306	5,015	4,570	2,437	2,198	2,348	964	937	1,317	1,758	1,346	1,860	1,111	1,252
Retained Earnings	-155,392	-157,901	-164,176	-197,328	-220,665	-336,218	-361,426	-345,859	-327,849	-287,984	-311,362	-291,107	-263,443	-253,642	-260,833	-224,975	-173,910	-99,841	-36,329	-12,445
Retained Earnings Total Equity	0	-157,901	-164,176	-197,328	-220,665	-336,218	-361,426	-345,859	-327,849	-287,984	-311,362	0	-263,443	0	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	0	0	27,000	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	9,404	11,141	10,055	13,614	12,455	0	0	0	0	0	0	0	0	0	0	0	0	0	142	367
Short Term Debt	2,398	2,328	2,311	2,117	2,147	0	27,000	0	0	6,749	0	0	0	2,266	0	0	0	-129,950	142	211
Short Term Investments	252,443	331,830	380,742	306,709	267,057	196,355	109,786	100,914	92,337	68,921	65,586	31,631	60,961	155,478	0	7,379	43,244	942	10,141	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	648,440	634,247	593,792	533,456	483,748	332,130	205,425	210,374	213,050	171,704	143,349	135,448	182,618	213,101	225,714	49,934	96,861	36,260	35,753	17,752
Total Current Assets	432,946	519,292	478,301	409,145	354,136	299,132	169,857	174,175	166,547	141,730	135,614	125,968	153,501	202,212	212,950	47,746	86,955	33,820	33,372	16,450
Total Current Liabilities	87,697	91,436	74,419	65,936	59,505	53,015	70,363	50,320	51,317	7,786	32,851	32,263	31,619	31,028	31,534	3,411	12,778	9,106	5,064	1,623
Total Liab	103,530	107,049	88,864	80,190	72,803	56,708	74,038	79,044	80,023	10,887	99,225	125,543	149,144	175,371	202,683	3,914	13,132	9,503	5,088	1,809
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	544,910	527,198	504,928	453,266	410,945	275,422	131,387	131,330	133,027	160,817	44,124	9,905	33,474	37,730	23,031	46,020	83,729	26,757	30,665	15,944
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31
Accounts Payable	7,145	3,488	2,170	3,800	12,690	13,433	16,412	14,327	925	1,299	2,117	26,105	31,509	29,086	28,398	26,045	27,590	26,992	29,307	27,423	21,584	19,046	18,562	17,242	20,335	18,921	19,126	18,025	16,196	17,572	17,933	22,664	15,767	45,889	1,631	1,490	835	547	248	953	661	369	1,167	1,113	287	1,090	1,689	780	996	1,333	1,337	834	648	295	1,020	868	2,424	6,346	6,917	1,415	512	899	5,826	1,826	2,988	3,446	2,600	2,010	2,783	2,112	5,063	3,378	2,255	0	0	0	719
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-30	-967	-865	-255	-1,193	-1,485	-1,431	-1,328	-175	111	103	192	239	379	596	781	249	211	386	135	1	70	79	-28	-34	73	11	50	58	142	124	92	39	37	27	27	16	4	10	8	21	0	0	0	10	23	5	27	21	44	85	99	2	52	56	17	-2,346	0	0	-1	-1,917	-242	-15	30	12	13	-8	-17	-3	-15	-16	-18	-18,784	0	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	9,404	7,472	7,942	10,733	11,141	11,102	11,531	11,957	12,366	12,752	10,740	13,251	13,614	13,537	13,901	14,240	14,602	14,916	15,249	15,573	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	58	58	57	57	57	57	57	56	56	56	56	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	693,835	690,586	686,235	681,847	677,955	674,001	669,223	664,408	660,086	656,057	650,300	645,656	642,398	635,730	631,307	625,524	621,559	615,047	611,587	607,873	604,889	599,480	492,802	489,939	486,400	481,551	477,087	474,234	466,272	463,084	460,794	458,908	453,269	450,609	448,744	358,728	357,119	355,644	355,432	353,708	303,357	301,733	300,974	300,039	299,463	298,270	296,868	295,530	294,271	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	135,821	183,186	150,031	354,171	135,029	49,397	58,226	66,927	52,071	50,522	57,242	72,132	61,031	56,973	95,305	64,950	45,072	39,208	46,543	34,379	61,005	60,778	60,891	155,293	33,627	22,586	14,232	20,111	40,426	32,765	23,194	38,740	50,843	46,786	48,337	32,809	60,901	15,308	16,994	43,260	64,764	142,172	103,633	109,931	88,772	104,515	94,388	108,094	87,923	60,326	50,386	52,520	42,559	102,468	145,651	169,946	205,295	17,418	24,014	33,833	39,079	41,439	56,504	56,015	41,930	59,954	47,631	64,221	30,929	31,900	46,440	12,520	21,013	0	0	0	16,259
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	388,264	489,858	489,351	501,496	466,859	454,791	440,858	435,176	432,813	405,968	396,493	378,162	367,740	348,548	339,849	312,326	312,129	237,785	280,161	267,836	257,360	240,579	231,216	248,834	143,413	139,881	137,118	137,756	141,340	142,579	135,989	138,330	143,180	144,315	146,637	134,329	129,822	56,089	63,585	100,402	130,350	142,172	103,633	110,932	120,403	134,404	144,701	157,250	148,884	161,448	188,399	194,555	198,037	202,060	207,117	202,424	205,295	20,683	29,023	42,644	46,458	51,664	63,068	71,044	85,173	105,429	119,662	126,920	31,871	42,996	60,171	20,119	31,154	0	0	0	0
Common Stock	58	58	57	57	57	57	57	56	56	56	56	56	55	55	55	54	54	53	53	53	52	52	52	52	45	45	45	45	44	44	43	43	43	43	42	42	41	34	34	34	33	33	28	28	28	28	28	28	28	28	28	28	28	28	28	28	28	27	27	27	27	27	27	27	27	27	27	27	22	22	22	0	16	0	0	0	0
Common Stock Shares Outstanding	57,532	57,595	57,536	57,400	57,189	56,969	56,821	56,105	57,230	57,041	56,903	56,505	56,505	55,209	55,081	54,870	54,974	54,542	54,580	52,753	55,217	54,710	53,946	48,225	44,931	44,885	44,719	44,398	43,969	43,515	43,203	43,104	42,815	42,435	41,992	41,745	39,421	33,887	33,875	33,679	33,284	31,333	28,377	28,346	28,233	28,227	28,227	28,227	28,227	28,107	28,103	28,937	28,937	28,467	28,438	28,319	28,319	27,197	26,901	26,653	26,653	26,651	26,649	26,648	26,648	26,613	26,567	25,340	25,340	21,872	19,184	469,970	469,970	469,970	469,970	469,970	0
Common Stock Total Equity	0	0	57	57	57	57	57	56	56	56	56	56	55	55	55	54	54	53	53	53	52	52	52	52	45	45	45	45	44	44	43	43	43	43	42	42	41	34	34	34	33	33	28	28	28	28	28	28	28	28	28	28	28	28	28	28	28	27	27	27	27	27	27	27	27	27	27	27	22	22	22	0	16	0	0	0	0
Current Deferred Revenue	0	-5,862	-4,536	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	174	31,232	31,059	31,059	26,789	26,789	26,789	26,789	26,789	26,789	26,789	26,789	27,242	26,789	26,789	26,789	26,789	26,789	26,789	26,789	26,789	0	0	0	0	0	0	0	0	0	141,229	142,411	129,950	136,251	137	134	130	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	89,072	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,639	1,639	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,101	39,154	46,853	54,595	66,374	73,183	79,993	86,685	90,275	99,824	106,368	112,739	117,525	124,416	131,040	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	121,369	17,428	17,808	18,186	18,565	18,944	19,323	19,702	20,081	20,450	20,820	21,189	21,559	21,929	22,298	22,667	23,037	23,407	23,783	24,162	24,542	24,922	25,319	25,717	26,069	26,501	26,933	27,365	27,819	29,924	32,867	35,809	38,752	41,695	44,638	47,580	26,724	11,319	11,855	12,472	5,037	5,414	5,791	6,163	6,532	6,909	7,286	7,658	8,027	8,404	8,781	9,153	9,522	9,899	10,276	10,648	11,017	11,394	11,771	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Inventory	1,357	1,006	1,080	1,105	1,194	1,590	1,496	1,290	1,025	902	1,055	1,361	1,280	1,322	1,384	1,320	1,140	1,019	1,057	1,112	994	887	1,193	1,011	840	921	742	816	779	865	927	938	1,294	3,797	4,962	4,923	5,170	1,016	1,093	192	530	530	28	21	57	161	165	0	0	0	0	0	0	0	0	1,480	2,399	1,758	1,272	0	0	2,803	0	515	718	2,228	2,130	575	924	0	0	0	0	0	0	0	0
Liabilities And Stockholders Equity	648,440	641,605	641,682	644,532	634,247	621,788	609,102	603,558	593,792	579,767	567,645	543,191	533,456	515,905	506,631	488,525	483,748	474,449	372,483	351,166	332,130	311,937	302,926	317,315	205,425	205,706	210,671	204,720	210,374	208,443	202,038	206,740	213,050	220,544	223,693	213,640	171,704	79,175	86,172	120,982	143,349	155,090	116,954	125,139	135,448	149,808	160,838	172,599	182,618	195,738	203,438	209,333	213,101	217,354	222,887	225,920	225,714	38,309	45,144	45,829	49,934	57,072	70,258	80,396	96,861	114,886	125,318	134,168	36,260	47,282	64,768	25,188	35,753	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	13,324	0	0	0	0	0	0	0	0	25,000	25,000	25,000	25,000	25,000	25,000	25,000	25,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	155
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	25,000	25,000	25,000	25,000	25,000	25,000	25,000	25,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	61,827	12,517	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	19,012	19,011	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	-126,417	-175,714	-142,089	-343,438	-123,888	-38,295	-46,695	-54,970	-42,016	-37,770	-46,502	-61,007	-47,417	-45,414	-83,585	-52,811	-32,617	-24,292	-31,294	-21,055	-61,005	-60,778	-60,891	-155,293	-33,627	-22,586	-14,232	-20,111	-40,426	-32,765	-23,194	-38,740	-50,843	-46,786	-48,337	-32,809	-60,901	-15,308	-16,994	-43,260	-64,764	-142,172	-103,633	-109,931	-88,772	-104,515	-94,388	-108,094	-87,923	-60,326	-50,386	-52,520	-42,559	-102,468	-145,651	-169,946	-205,295	-17,418	-24,014	-33,833	-39,079	-41,439	-56,504	-56,015	-41,930	-59,954	-47,631	-64,221	-30,929	-31,900	-46,391	-12,424	-20,870	0	0	0	0
Net Invested Capital	544,910	543,100	539,898	535,739	527,198	515,657	508,549	502,123	504,928	493,321	481,220	467,627	453,266	440,572	431,584	416,386	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	34,155	29,272	33,621	24,513	33,512	29,352	28,805	30,497	32,467	41,496	37,090	31,474	30,036	28,033	24,587	29,272	26,367	26,824	23,890	26,346	28,780	25,259	24,855	23,314	17,601	18,179	21,024	17,751	20,268	15,928	14,030	16,679	16,331	15,789	15,818	20,120	3,654	3,696	2,376	1,790	2,031	1,956	1,701	1,462	1,168	1,535	1,700	1,535	1,618	1,216	752	895	511	494	655	6,097	3,164	0	0	0	0	11	0	80	5	4	15	18	108	0	0	0	0	0	0	0	0
Net Tangible Assets	0	0	522,090	517,553	508,633	496,713	489,226	482,421	484,847	472,871	460,400	446,438	431,707	418,643	409,286	393,719	387,908	377,500	272,911	254,243	250,880	236,495	225,952	215,427	105,318	103,968	104,485	100,777	103,511	99,241	88,747	87,203	94,275	104,242	105,109	104,893	134,093	-10,256	-10,970	8,511	39,087	44,588	-765	318	3,373	8,443	12,798	19,262	25,447	29,278	30,757	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	345,249	451,735	446,107	439,913	427,856	414,483	408,495	401,526	403,882	389,811	374,663	359,440	343,209	328,175	319,269	301,524	294,631	220,014	253,226	247,223	246,117	232,565	222,221	210,480	99,494	98,183	99,173	95,594	123,855	119,727	108,615	107,409	115,230	127,988	129,180	130,378	133,944	25,993	32,926	60,113	102,763	115,165	76,420	84,139	93,705	105,221	115,603	128,687	121,882	131,079	158,665	165,215	169,546	173,915	176,106	178,913	181,416	16,682	20,092	40,282	44,335	50,625	55,417	61,902	74,178	93,554	113,936	121,844	24,714	34,736	45,232	11,595	28,308	0	0	0	0
Non Current Assets Total	215,494	105,033	108,178	110,825	114,955	114,682	112,207	111,290	115,491	117,959	120,993	121,967	124,311	126,371	125,770	127,779	129,612	194,439	56,681	44,668	32,998	33,130	33,824	34,880	35,568	35,987	36,062	36,158	36,199	38,035	41,662	44,291	46,503	46,667	49,320	51,473	29,974	14,337	14,952	15,465	7,735	8,020	8,599	9,027	9,480	9,955	10,849	11,250	29,117	31,019	11,913	12,082	12,528	11,345	11,801	12,258	12,764	13,235	13,719	2,066	2,188	2,466	5,159	8,176	9,905	6,018	2,351	5,410	2,440	2,459	2,511	2,599	2,381	0	0	0	0
Non Current Liabilities Other	8,827	6,196	6,445	14,999	15,613	13,508	12,153	10,693	14,445	14,449	3,696	13,780	14,254	13,974	13,455	12,917	13,298	13,546	13,213	13,486	3,693	4,278	4,774	4,216	3,675	3,701	3,817	3,610	3,724	3,597	3,663	3,688	3,706	3,718	3,753	4,378	0	113	140	0	0	0	0	0	0	0	0	278	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	15,833	13,668	14,387	14,999	15,613	13,508	12,153	10,693	14,445	14,449	14,436	13,780	14,254	13,974	13,455	12,917	13,298	13,546	13,213	13,486	3,693	4,278	4,774	4,216	3,675	3,701	3,817	3,610	28,724	28,597	28,663	28,688	28,706	28,718	28,753	29,378	3,101	39,267	46,993	54,595	66,374	73,183	79,993	86,685	93,280	99,824	106,368	113,017	117,525	124,416	131,040	137,729	144,343	151,100	157,856	164,539	171,149	506	505	504	503	497	491	422	354	281	254	448	397	242	175	130	24	0	0	0	0
Non Currrent Assets Other	9,516	9,808	9,479	9,993	10,909	9,884	8,848	8,928	8,147	8,506	8,003	6,389	6,641	6,357	3,569	3,719	3,851	4,541	4,423	4,218	4,039	3,629	3,705	4,058	4,193	4,038	3,420	3,332	3,365	3,380	4,549	4,131	3,181	813	813	813	813	785	785	785	500	500	600	600	600	600	1,030	1,114	1,114	1,114	530	430	430	430	430	430	430	430	430	430	430	580	580	580	580	580	580	-2,996,601	580	610	610	1,270	1,270	0	0	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	0	85,417	84,882	81,535	79,726	83,025	84,611	86,644	86,744	88,157	90,215	89,127	90,360	91,531	93,613	4,423	4,218	4,039	3,629	3,705	4,058	30,262	30,539	30,353	30,697	31,184	33,304	37,416	39,940	41,933	42,508	45,451	48,393	27,537	12,104	12,640	13,257	5,537	5,914	6,391	6,763	7,132	7,509	8,316	8,772	28,153	30,168	10,950	11,222	11,591	10,329	10,708	11,079	11,447	11,824	12,201	430	430	580	3,138	6,574	8,560	4,573	580	3,580	580	610	610	1,270	1,270	0	0	0	50
Other Current Assets	9,170	16,436	9,452	6,593	17,727	21,373	25,736	25,305	11,996	13,442	12,014	10,227	10,089	11,631	15,041	17,828	14,500	14,382	10,694	11,204	11,998	12,082	11,838	9,276	8,003	10,713	15,127	11,032	11,788	11,036	9,430	6,502	5,742	9,976	6,956	324	3,084	182	4,166	3,133	2,703	2,412	2,993	3,288	3,910	3,753	3,423	2,564	2,999	2,055	2,374	1,801	2,025	3,456	3,314	3,662	2,093	2,633	1,129	1,119	1,287	128	2,030	581	1,059	1,207	1,161	1,245	918	1,828	2,087	2,471	2,218	0	0	0	191
Other Current Liab	78,154	84,837	87,397	87,648	76,418	76,991	69,743	74,118	71,183	68,403	67,730	59,658	32,310	59,381	59,411	57,121	57,358	57,873	60,319	57,026	53,015	46,242	46,881	71,955	50,028	71,536	75,436	72,968	34,124	50,681	33,828	32,376	35,550	45,889	43,562	30,299	28	7,066	6,987	13,392	5,401	4,747	3,979	4,071	5,187	6,753	5,908	5,093	3,381	3,410	2,513	2,141	1,324	1,776	1,408	1,353	2,321	2,046	4,415	2,065	2,898	3,082	3,856	8,492	9,790	11,868	141	4,904	6,323	-128,275	11,777	7,387	2,536	0	0	0	693
Other Liab	0	0	0	0	6,800	4,605	2,867	1,033	4,390	3,992	3,696	2,655	2,757	2,415	1,735	778	843	753	221	162	3,693	4,278	4,774	4,216	3,646	3,701	3,817	3,610	28,724	28,597	28,663	28,688	28,706	28,718	28,753	29,378	3,101	39,267	46,993	54,595	66,374	73,183	79,993	86,685	93,280	99,824	106,368	113,017	117,525	124,416	131,040	137,729	144,343	151,100	157,857	164,539	171,149	506	505	504	503	497	491	422	354	280	253	448	397	242	175	130	24	0	0	0	30
Other Stockholder Equity	700,274	697,001	693,835	690,586	686,235	681,847	677,955	674,001	669,223	664,408	660,086	656,057	452,972	645,656	642,398	635,730	631,307	625,524	621,559	615,047	611,587	607,873	604,889	599,480	492,802	489,939	486,400	481,551	477,087	474,234	466,272	463,084	460,794	458,908	453,269	450,609	448,744	358,728	357,119	355,644	355,432	353,708	303,357	301,733	300,974	300,039	299,463	298,270	296,868	295,530	294,271	292,946	291,342	289,920	288,991	286,890	283,837	280,980	277,150	273,297	272,885	270,280	266,675	262,706	257,600	252,412	247,232	242,030	126,579	124,894	123,387	6,737	85,762	0	0	0	0
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	61,795	61,795	0	0	0	28,309
Property Plant And Equipment Gross	20,321	9,556	9,946	10,430	10,973	10,856	0	0	0	0	13,529	14,034	4,136	14,227	14,345	14,752	15,044	15,592	15,958	16,288	4,417	4,579	4,800	5,105	5,306	5,448	5,709	5,461	5,015	4,731	4,246	4,351	4,570	4,159	3,869	3,080	2,437	2,233	2,312	2,208	2,198	2,106	2,208	2,264	2,348	2,446	2,533	2,478	964	851	963	860	937	1,015	1,095	1,179	1,316	1,411	1,518	1,635	1,758	1,886	2,021	1,602	1,346	1,445	1,771	1,830	1,860	1,848	1,900	1,328	1,111	0	0	0	0
Property Plant And Equipment Net	9,140	9,556	9,946	10,430	10,973	10,856	11,349	11,862	12,385	12,898	13,529	14,034	14,595	14,227	14,345	14,752	15,044	15,592	15,958	16,288	4,417	4,579	4,800	5,105	5,306	5,448	5,709	5,461	5,015	4,731	4,246	4,351	4,570	4,159	3,869	3,080	2,437	2,233	2,312	2,208	2,198	2,106	2,208	2,264	2,348	2,446	2,533	2,478	964	851	963	860	937	1,015	1,095	1,179	1,316	1,411	1,518	1,635	1,758	1,886	2,021	1,602	1,346	1,445	1,771	1,830	1,860	1,848	1,900	1,328	1,111	0	0	0	0
Property Plant Equipment	0	0	2,164	2,333	2,573	2,594	11,349	2,917	12,385	12,898	13,529	3,840	4,136	3,921	3,744	3,877	3,864	4,156	4,240	4,294	4,417	4,579	4,800	5,105	5,306	5,448	5,709	5,461	5,015	4,731	4,246	4,351	4,570	4,159	3,869	3,080	2,437	2,233	2,312	2,208	2,198	2,106	2,208	2,264	2,348	2,446	2,533	2,478	964	851	963	860	937	1,015	1,095	1,179	1,317	1,411	1,519	1,636	1,758	1,886	2,021	1,602	1,346	1,445	1,770	1,830	1,860	1,848	1,900	1,328	1,111	0	0	0	1,252
Retained Earnings	-155,392	-152,992	-153,129	-154,649	-157,901	-164,762	-168,032	-170,606	-164,176	-171,254	-179,025	-188,678	-197,328	-205,518	-211,465	-220,179	-220,665	-224,881	-325,304	-336,830	-336,218	-346,578	-353,749	-358,360	-361,426	-359,588	-355,038	-353,504	-345,859	-345,255	-344,825	-340,207	-327,849	-313,051	-303,591	-298,205	-287,984	-357,703	-356,278	-334,703	-311,362	-303,739	-298,359	-295,280	-291,107	-284,738	-279,412	-271,405	-263,443	-257,920	-254,846	-253,505	-253,641	-255,840	-259,025	-260,304	-260,833	-251,596	-243,871	-231,478	-224,975	-217,470	-206,601	-193,106	-173,910	-153,162	-131,218	-115,233	-99,841	-87,949	-75,825	-54,452	-36,329	0	0	0	0
Retained Earnings Total Equity	0	0	-153,129	-154,649	-157,901	-164,762	-168,032	-170,606	-164,176	-171,254	-179,025	-188,678	-197,328	-205,518	-211,465	-220,179	-220,665	-224,881	-325,304	-336,830	-336,218	-346,578	-353,749	-358,360	-361,426	-359,588	-355,038	-353,504	-345,859	-345,255	-344,825	-340,207	-327,849	-313,051	-303,591	-298,205	-287,984	-357,703	-356,278	-334,703	-311,362	-303,739	-298,359	-295,280	-291,107	-284,738	-279,412	-271,405	-263,443	-257,920	-254,846	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,249	0	0	0	27,000	27,000	27,000	25,000	25,000	0	25,000	25,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	9,404	7,472	7,942	10,733	11,141	11,102	11,531	11,957	10,055	12,752	10,740	11,125	13,614	11,559	11,720	12,139	12,455	14,916	15,249	13,324	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	49	96	142	0	0	0	0
Short Term Debt	2,398	2,374	2,366	2,346	2,328	2,199	2,245	2,297	2,311	2,295	2,142	2,126	2,117	1,978	2,181	2,101	2,147	2,123	2,257	2,249	0	0	0	27,000	27,000	27,000	25,000	25,000	0	25,000	25,000	0	0	0	0	0	6,749	0	0	0	0	0	0	0	0	0	0	0	0	2,108	2,221	2,272	2,266	3,235	5,764	5,740	0	0	0	0	0	0	0	0	0	0	-134,939	-142,411	-129,950	0	49	96	142	0	0	0	0
Short Term Investments	252,443	306,672	339,320	147,325	331,830	405,394	382,632	368,249	380,742	355,446	339,251	306,030	306,709	291,575	244,544	247,376	267,057	198,577	233,618	233,457	196,355	179,801	170,325	93,541	109,786	117,295	122,886	117,645	100,914	109,814	112,795	99,590	92,337	97,529	98,300	101,520	68,921	40,781	46,591	57,142	65,586	530	430	1,001	31,631	29,889	50,313	49,156	60,961	101,122	138,013	142,035	155,478	99,592	61,467	32,478	0	3,265	5,009	8,811	7,379	10,225	6,565	15,028	43,244	45,474	72,031	62,698	942	11,097	13,731	7,599	10,141	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	648,440	641,605	641,682	644,532	634,247	621,788	609,102	603,558	593,792	579,767	567,645	543,191	533,456	515,905	506,631	488,525	483,748	474,449	372,483	351,166	332,130	311,937	302,926	317,315	205,425	205,706	210,671	204,720	210,374	208,443	202,038	206,740	213,050	220,544	223,693	213,640	171,704	79,175	86,172	120,982	143,349	155,090	116,954	125,139	135,448	149,808	160,838	172,599	182,618	195,738	203,438	209,333	213,101	217,354	222,887	225,920	225,714	38,309	45,144	45,829	49,934	57,072	70,258	80,396	96,861	114,886	125,318	134,168	36,260	47,282	64,768	25,188	35,753	0	0	0	17,752
Total Current Assets	432,946	536,572	533,504	533,707	519,292	507,106	496,895	492,268	478,301	461,808	446,652	421,224	409,145	389,534	380,861	360,746	354,136	280,010	315,802	306,498	299,132	278,807	269,102	282,435	169,857	169,719	174,609	168,562	174,175	170,408	160,376	162,449	166,547	173,877	174,373	162,167	141,730	64,838	71,220	105,517	135,614	147,070	108,355	116,112	125,968	139,853	149,989	161,349	153,501	164,719	191,525	197,251	200,573	206,010	211,086	213,662	212,950	25,074	31,424	43,763	47,746	54,606	65,099	72,220	86,955	108,868	122,968	128,758	33,820	44,824	62,258	22,590	33,372	0	0	0	0
Total Current Liabilities	87,697	84,837	87,397	93,794	91,436	92,623	88,400	90,742	74,419	71,997	71,989	61,784	65,936	61,359	61,592	59,222	59,505	59,996	62,576	59,275	53,015	46,242	46,881	71,955	70,363	71,536	75,436	72,968	50,320	50,681	51,761	55,040	51,317	45,889	45,193	31,789	7,786	38,845	38,294	45,404	32,851	31,905	31,935	31,973	32,263	34,632	34,386	32,662	31,619	33,640	32,860	32,036	31,027	32,095	34,980	34,750	31,534	8,392	11,332	3,481	3,411	3,981	9,682	10,318	12,778	15,315	9,032	6,914	9,106	10,088	17,025	10,995	5,064	0	0	0	1,623
Total Liab	103,530	98,505	101,784	108,793	107,049	106,131	100,553	101,435	88,864	86,446	86,425	75,564	80,190	75,333	75,047	72,139	72,803	73,542	75,789	72,761	56,708	50,520	51,655	76,171	74,038	75,237	79,253	76,578	79,044	79,278	80,424	83,728	80,023	74,607	73,946	61,167	10,887	78,112	85,287	99,999	99,225	105,088	111,928	118,658	125,543	134,456	140,754	145,679	149,144	158,056	163,900	169,765	175,370	183,195	192,837	199,289	202,683	8,898	11,837	3,984	3,914	4,478	10,173	10,740	13,132	15,595	9,286	7,363	9,503	10,331	17,201	11,126	5,088	0	0	0	1,808
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	544,910	543,100	539,898	535,739	527,198	515,657	508,549	502,123	504,928	493,321	481,220	467,627	453,266	440,572	431,584	416,386	410,945	400,907	296,694	278,405	275,422	261,417	251,271	241,144	131,387	130,469	131,418	128,142	131,330	129,165	121,614	123,012	133,027	145,937	149,747	152,473	160,817	1,063	885	20,983	44,124	50,002	5,026	6,481	9,905	15,352	20,084	26,920	33,474	37,682	39,538	39,568	37,731	34,159	30,050	26,631	23,031	29,411	33,307	41,844	46,020	52,594	60,085	69,656	83,729	99,290	116,033	126,806	26,757	36,952	47,568	14,063	30,665	0	0	0	15,944
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Begin Period Cash Flow	135,029	52,590	61,613	45,650	61,749	34,335	40,426	50,843	60,901	64,764	88,772	87,923	42,559	205,295	39,079	41,930	30,929	21,013	16,260	7,166
Capital Expenditures	383	679	552	1,795	1,019	25,368	1,664	1,407	2,527	8,769	176	2,017	275	-380	12,000	944	279	1,354	292	415
Cash And Cash Equivalents Changes	0	82,643	-8,932	15,910	-16,098	27,452	-6,799	-10,417	-10,058	-3,863	-24,008	849	45,364	0	0	0	0	0	0	0
Cash Flows Other Operating	0	-151	4,387	6,972	-2,003	3,965	-7,444	-7,585	32,323	-318	1,264	999	-1,240	0	0	0	0	0	0	0
Change In Cash	792	82,908	-9,023	15,963	-16,099	27,414	-6,799	-10,417	-10,058	-3,863	-24,008	849	45,364	-162,736	166,216	-2,850	11,001	9,916	4,753	9,094
Change In Working Capital	-747	6,074	2,737	4,317	3,125	-7,790	-26	-11,108	29,465	-32,960	-26,023	-25,861	-28,794	-20,378	192,402	-8,574	3,777	5,534	686	417
Change Receivables	0	-1,089	-2,469	-3,767	2,342	-11,207	2,525	-4,298	-12,677	-1,623	-863	450	-1,107	0	0	0	0	0	0	0
Change To Account Receivables	-707	-1,089	-2,469	-3,767	2,342	-11,207	2,525	-4,298	-12,677	-1,623	-863	450	-1,107	2,653	-3,164	0	0	0	0	28
Change To Inventory	-771	-4,479	-2,233	-2,876	-722	70	-1,060	200	387	-2,210	1,255	-57	-1,670	2,399	-2,399	0	0	0	0	0
Change To Liabilities	0	11,793	3,040	3,759	3,508	-618	5,953	575	9,432	-28,809	-26,424	-25,427	-26,447	0	1,334	0	3,669	4,338	3,375	515
Change To Netincome	0	19,865	23,847	21,307	-72,524	11,833	11,052	9,085	8,618	-71,738	4,604	4,094	7,322	3,898	0	0	0	0	0	0
Change To Operating Activities	0	-151	4,399	7,201	-2,003	3,965	-7,444	-7,585	32,497	177	0	0	0	0	0	0	0	0	0	0
Depreciation	3,010	2,733	2,841	2,864	2,892	2,956	2,984	11,868	13,554	2,784	1,927	2,128	1,964	1,831	1,425	531	572	575	424	377
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	135,821	135,498	52,590	61,613	45,650	61,749	33,627	40,426	50,843	60,901	64,764	88,772	87,923	42,559	205,295	39,079	41,930	30,929	21,013	16,260
Exchange Rate Changes	0	0	0	0	0	0	40	6	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	12,418	31,305	63,662	49,980	44,928	4,618	-3,647	-9,510	9,922	-90,323	-39,768	-46,934	-28,685	-10,898	157,336	-46,899	-51,921	-52,974	-18,006	-9,029
Investments	107,155	50,604	-76,144	-39,704	-67,290	-84,292	-8,567	-8,618	-24,071	-3,513	-34,099	47,771	74,624	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	100,870	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	2,509	6,275	33,152	23,337	115,553	25,208	-15,567	-18,010	-39,865	20,186	-20,255	-27,664	-9,802	7,192	-35,859	-51,064	-74,070	-63,511	-23,884	-9,474
Other Cashflows From Financing Activities	-12,056	734	3,550	5,634	6,264	6,256	5,251	7,751	4,091	2,415	1,354	12	25	3,784	1,619	43,088	-48,760	-143	-224	18,345
Other Cashflows From Investing Activities	0	0	0	0	-67,290	-25,000	124	-46	-24,071	-7,755	0	0	-600	0	0	0	0	0	0	0
Other Non Cash Items	-4,725	-507	3,365	1,708	-1,314	167	587	708	657	-77,616	155	1,826	900	-2,703	138	-235	18,051	5,753	5,060	66
Sale Purchase Of Stock	0	734	3,550	5,634	6,264	107,126	5,251	7,751	4,374	65,164	50,055	12	25	0	0	0	0	0	0	0
Stock Based Compensation	14,040	16,279	15,374	13,360	13,458	11,666	10,465	8,543	7,961	5,878	4,604	4,094	5,501	4,981	11,230	13,388	19,623	6,131,827	0	0
Total Cash From Financing Activities	605	734	3,550	5,634	6,264	107,126	5,251	7,751	4,091	89,728	49,859	12	25	3,784	1,619	0	111,403	53,314	33,294	18,146
Total Cash From Operating Activities	12,801	31,984	64,214	51,775	45,947	29,986	-1,983	-8,103	12,449	-81,554	-39,592	-44,917	-28,410	-10,898	169,336	-45,955	-51,641	-51,620	-17,714	-8,615
Total Cashflows From Investing Activities	0	49,925	-76,696	-41,499	-68,309	-109,660	-10,107	-10,071	-26,598	-12,037	-34,275	45,754	73,749	0	0	43,088	0	8,221	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31
Begin Period Cash Flow	183,655	150,500	354,640	135,498	49,866	58,742	67,445	52,590	51,041	57,822	72,711	61,613	57,553	95,883	65,527	45,650	39,950	47,287	35,122	61,749	61,522	61,635	156,037	34,335	22,586	14,232	20,111	40,426	32,765	23,194	38,740	50,843	46,786	48,337	32,809	60,901	15,308	16,994	43,260	64,764	142,172	103,633	109,931	88,772	104,515	94,388	108,094	87,923	60,326	50,386	52,520	42,559	102,468	145,651	169,946	205,295	17,418	24,014	33,833	39,079	41,439	56,504	56,015	41,930	59,954	47,631	64,221	30,929	31,900	46,440	12,520	21,013	22,265	8,447	10,801	16,260	0
Capital Expenditures	253	24	55	51	263	148	193	75	134	10	298	130	966	246	210	373	68	294	264	393	22	136	25,075	135	191	371	624	478	697	599	111	-219	714	874	156	783	338	53	243	8,135	97	7	49	23	7	17	148	1,845	77	34	164	-77	-78	-80	-84	5,000	5,000	-108	-117	-122	944	464	293	186	30	47	84	119	167	316	513	358	196	38	22	36	415
Cash And Cash Equivalents Changes	0	0	-204,114	219,097	85,449	-8,936	-8,782	14,912	1,650	-6,820	-14,875	11,113	4,048	-38,348	30,338	19,872	5,677	-7,318	12,172	-26,629	251	-99	-94,384	121,684	11,041	8,354	-5,879	-20,315	7,661	9,571	-15,546	-12,103	4,057	-1,551	15,528	-28,092	45,593	-1,686	-26,266	-21,504	-77,408	38,539	-6,298	21,159	-15,743	10,127	-13,706	20,171	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-6,620	24,511	7,129	8,381	-1,407	-14,254	1,914	-1,312	3,098	687	3,430	2,948	2,934	-2,340	-931	-3,791	1,766	953	3,152	297	-2,906	3,422	-1,958	1,249	-2,108	-4,627	255	-1,538	-1,644	-4,658	39,215	-3,020	-4,453	581	764	381	-1,034	-429	-291	239	2,437	-1,121	-587	101	-956	2,441	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-47,365	33,155	-204,140	219,142	85,632	-8,876	-8,703	14,855	1,549	-6,781	-14,889	11,098	4,060	-38,330	30,356	19,877	5,700	-7,337	12,165	-26,627	227	-113	-94,402	121,702	11,041	8,354	-5,879	-20,315	7,661	9,571	-15,546	-12,103	4,057	-1,551	15,528	-28,092	45,593	-1,686	-26,266	-21,504	-77,408	38,539	-6,298	21,159	-15,743	10,127	-13,706	20,171	27,597	9,940	-2,134	9,961	-59,909	-43,183	-24,295	-35,350	187,878	-6,597	-9,819	-5,246	-2,359	-15,065	488	14,086	-18,025	12,324	-16,590	33,292	-971	-14,540	33,920	-8,493	-1,252	13,818	-2,354	-5,459	0
Change In Working Capital	2,820	-6,779	-18,828	22,040	-1,349	7,359	114	-50	13,032	-6,550	2,269	-6,014	4,040	-3,111	10,352	-6,964	-12	-9,401	5,688	6,850	2,050	-1,423	-3,458	-4,959	1,715	3,111	-4,100	-752	-5,113	-4,107	-3,891	2,003	8,728	-738	12,125	9,350	-7,832	-8,289	-17,332	493	-6,335	-6,916	-6,272	-6,500	-9,029	-7,855	-6,030	-2,947	-10,661	-6,073	-6,295	-5,765	-6,150	-9,863	561	-4,927	195,521	-4,929	1,570	240	1,241	-6,151	-1,685	-1,980	-886	6,248	454	-2,039	-914	-6,345	6,967	5,826	-150	288	260	288	0
Change Receivables	0	0	-9,100	8,901	-4,071	-593	1,618	1,957	9,015	-4,420	-5,581	-1,483	-1,993	-3,446	4,577	-2,905	428	-2,937	2,417	2,434	-3,521	-392	-1,581	-5,713	436	2,845	-3,272	2,516	-4,350	-2,249	2,649	-348	-542	29	4,302	-16,466	42	-1,320	-685	340	-75	-315	-179	-294	367	165	-165	83	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-4,836	4,328	-9,100	8,901	-4,071	-593	1,618	1,957	9,015	-4,420	-5,581	-1,483	-1,993	-3,446	4,577	-2,905	428	-2,937	2,417	2,434	-3,521	-392	-1,581	-5,713	436	2,845	-3,272	2,516	-4,350	-2,249	2,649	-348	-542	29	4,302	-16,466	42	-1,320	-685	340	-75	-315	-179	-294	367	165	-165	83	-402	-464	143	-384	-17	161	5,376	-2,867	-3,164	-20,554	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	28
Change To Inventory	-427	-554	136	74	-1,130	-1,767	-403	-1,179	-77	-790	-1,408	42	252	-3,138	-66	76	174	-705	-147	-44	-145	286	-134	63	-164	-889	76	-83	137	172	-239	130	-986	1,165	253	-45	-942	-175	-901	-192	200	950	531	-426	104	4	-403	2,425	-3,484	1,019	-252	1,047	0	3,221	1,480	919	-640	-486	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	-3,244	-10,791	-3,277	1,338	306	13,426	2,180	-28	6,160	-5,272	2,351	525	2,678	-1,795	317	-1,968	1,652	3,507	2,564	-1,614	1,163	-2,731	3,401	-94	1,204	1,442	-1,155	-492	-4,657	6,879	-28,959	1,088	12,023	25,041	-7,696	-7,175	-14,712	774	-5,969	-6,840	-6,730	-6,885	-8,913	-6,299	-4,744	-5,471	2,184	2,771	1,878	1,003	0	0	0	0	1,334	0	2,921	70	0	0	0	0	3,669	6,205	0	0	4,338	5,186	11,859	5,750	3,375	0	0	0	515
Change To Netincome	0	0	5,439	7,474	5,044	2,688	2,386	9,747	5,593	7,033	6,383	5,364	6,005	5,575	4,590	5,137	5,324	-84,971	3,524	3,599	2,936	2,912	2,947	3,038	2,970	2,960	2,733	2,389	2,162	2,583	2,074	2,266	2,544	2,061	2,068	1,945	-75,985	1,411	1,443	1,393	1,283	1,539	830	952	923	576	1,193	1,402	0	0	0	6	3,898	3,234	5,764	5,740	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	0	0	7,129	8,381	-1,407	-14,254	1,914	-1,312	3,098	699	3,430	2,948	3,163	-2,340	-931	-3,791	1,766	953	3,152	297	-2,906	3,422	-7,444	1,249	-2,108	-446	-7,585	-819	-3,096	0	32,497	0	0	0	177	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1,158	580	602	670	663	678	690	702	706	708	712	715	713	718	712	721	735	726	719	712	752	748	755	701	771	774	735	704	2,386	3,162	3,158	3,162	3,105	3,100	3,065	4,284	670	668	756	690	488	486	477	476	482	481	465	700	562	523	433	446	455	456	457	463	472	484	346	123	128	143	137	123	125	153	145	149	160	151	144	120	107	106	97	113	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	136,290	183,655	150,500	354,640	135,498	49,866	58,742	67,445	52,590	51,041	57,822	72,711	61,613	57,553	95,883	65,527	45,650	39,950	47,287	35,122	61,749	61,522	61,635	156,037	33,627	22,586	14,232	20,111	40,426	32,765	23,194	38,740	50,843	46,786	48,337	32,809	60,901	15,308	16,994	43,260	64,764	142,172	103,633	109,931	88,772	104,515	94,388	108,094	87,923	60,326	50,386	52,520	42,559	102,468	145,651	169,946	205,295	17,418	24,014	33,833	39,079	41,439	56,504	56,015	41,930	59,954	47,631	64,221	30,929	31,900	46,440	12,520	21,013	22,265	8,447	10,801	16,260
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9	14	16	1	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-3,985	-2,074	-13,275	31,752	9,153	12,689	5,492	3,971	26,473	9,407	18,719	9,063	18,336	9,128	23,796	-1,280	9,723	5,704	20,251	9,250	15,241	8,558	-20,684	1,503	3,275	1,797	-2,884	-5,835	-1,880	642	-3,373	-4,899	-1,070	-5,725	11,945	4,772	-13,724	-7,652	-36,908	-32,039	-12,250	-10,278	-8,092	-9,148	-13,856	-10,181	-12,362	-10,535	-12,434	-7,204	-5,619	-3,264	-5,096	-5,074	4,098	-4,826	184,292	-8,714	-7,447	-3,795	-5,450	-13,753	-11,401	-16,296	-16,651	-10,862	-10,883	-13,524	-11,283	-17,240	-13,374	-11,077	-6,097	-4,566	-3,712	-3,631	0
Investments	-43,783	35,327	-190,839	187,345	75,691	-21,629	-14,399	10,941	-25,864	-16,598	-33,883	201	-15,720	-47,599	2,942	20,673	-6,162	-13,580	-11,490	-36,058	-15,782	-8,769	-76,188	16,447	7,552	5,775	-5,204	-16,690	8,831	2,967	-13,188	-7,228	5,128	595	2,991	-32,785	-28,170	5,768	10,510	8,379	-65,599	0	1,000	30,500	-1,899	20,308	-1,344	30,706	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-2,400	137	1,520	3,252	6,861	3,270	2,574	-6,430	7,078	7,771	9,653	8,650	8,190	5,947	8,714	486	4,216	100,423	11,526	-612	10,360	7,171	4,611	3,066	-1,838	-4,550	-1,534	-7,645	-604	-430	-4,618	-12,358	-14,798	-9,460	-5,386	-10,221	69,719	-1,425	-21,575	-26,533	-7,623	-5,380	-3,079	-4,173	-6,369	-5,326	-8,007	-7,962	-5,523	-3,074	-1,341	136	2,199	3,184	1,279	529	-9,237	-7,725	-12,392	-6,504	-7,504	-10,869	-13,495	-19,196	-20,748	-21,944	-15,985	-15,393	-11,891	-12,124	-21,373	-18,122	-6,844	-5,705	-5,468	-5,867	0
Other Cashflows From Financing Activities	-43,783	35,327	-190,894	187,294	-129	4	125	10,866	-2,509	371	289	1,849	-4,202	123	3,600	479	-4,148	558	3,411	179	792	112	2,686	2,666	-5,170	768	2,193	2,209	-7,001	5,962	1,015	24	-4,375	3,579	592	-79	174	198	32	2,011	488	48,817	794	-193	-1,906	20,291	-1,492	28,861	-5	-4,035,521	3,485	13,225	-272	-4,207	-2,717	1,933	-1,284	401	-3,255	-1,451	3,090	-1,776	11,596	30,178	-1,454	23,111	-5,771	-64,646	0	-49	-47	-46	-18,545	18,500	1,378	-1,770	0
Other Cashflows From Investing Activities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	20,673	-67,290	-61,128	-47,548	-36,058	-84,292	0	-25,000	0	124	0	0	0	-46	0	0	0	-46	0	0	0	245	0	100	-7,855	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-1,099	-1,884	-1,218	-524	-959	-521	344	629	704	991	897	773	751	911	19	27	-204	777	423	317	14	40	226	-113	188	189	77	133	149	516	15	28	722	187	229	197	-77,574	37	43	53	34	0	1	120	21,295	-3,500	-8,007	-7,962	126	-3,074	259	315	-2,668	21	-29	-27	15	26	58	38	-12,702	3,588	3,935	4,944	4,886	4,727	4,587	3,878	1,500	1,394	1,401	1,458	985	783	1,420	1,872	0
Sale Purchase Of Stock	0	0	0	0	605	4	125	0	1,041	371	289	1,849	1,432	123	3,600	479	2,116	558	3,390	200	792	112	2,488	103,734	81	768	2,193	2,209	750	5,962	1,015	24	0	3,579	592	203	62,487	198	32	2,447	441	48,817	795	2	12	0	0	0	0	4,035,526	0	0	0	3,786	2,638	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	3,273	3,167	3,249	4,351	3,783	3,888	3,830	4,778	3,774	3,951	3,740	3,909	3,212	3,135	3,069	3,944	3,668	3,407	3,101	3,282	2,922	2,872	2,721	3,151	2,782	2,771	2,656	2,256	2,103	2,100	2,074	2,266	1,887	2,061	2,068	1,945	1,631	1,411	1,443	1,393	1,283	1,539	830	952	923	576	1,193	1,402	1,318	1,254	1,325	1,604	1,335	887	1,639	1,121	2,522	3,429	2,971	2,309	13,388	0	0	0	19,623	0	0	4,107,972	6,131,827	0	0	1,520,317	0	0	0	0	0
Total Cash From Financing Activities	0	0	0	0	605	4	125	125	1,041	371	289	1,849	1,432	123	3,600	479	2,116	558	3,411	179	792	112	2,488	103,734	81	768	2,193	2,209	750	5,962	1,015	24	-1	3,579	592	-79	87,487	198	32	2,011	441	48,817	794	-193	12	0	0	20	20	5	0	1,347	1,347	42	462	1,933	335	401	883	0	17	0	0	45	45	24	-13	111,348	78	-49	53,331	-46	14,959	18,464	-39	-89	18,146
Total Cash From Operating Activities	-3,732	-2,050	-13,220	31,803	9,416	12,837	5,685	4,046	26,607	9,397	19,017	9,193	19,302	9,374	24,006	-907	9,791	5,998	20,515	9,643	15,263	8,694	4,391	1,638	3,466	2,168	-2,260	-5,357	-1,183	1,241	-3,262	-4,899	-356	-4,851	12,101	5,555	-13,386	-7,599	-36,665	-23,904	-12,153	-10,271	-8,043	-9,125	-13,849	-10,164	-12,214	-8,690	-12,357	-7,170	-5,619	-3,264	-5,096	-5,074	4,098	-4,826	189,292	-8,714	-7,447	-3,795	-5,450	-13,289	-11,108	-16,109	-16,622	-10,815	-10,799	-13,405	-11,116	-16,924	-12,861	-10,719	-5,901	-4,528	-3,691	-3,595	0
Total Cashflows From Investing Activities	0	0	-190,894	187,294	75,428	-21,777	-14,592	10,866	-25,998	-16,588	-34,181	71	-16,686	-47,845	2,732	20,300	-6,230	-13,874	-11,754	-36,451	-15,804	-8,905	-101,263	16,312	7,485	5,404	-5,828	-17,168	8,088	2,368	-13,299	-7,228	4,414	-279	2,835	-33,568	-28,508	5,715	10,367	389	-65,696	-7	951	30,477	-1,906	20,291	-1,492	28,861	73,749	33,815	16,710	13,225	0	0	0	0	0	0	0	0	43,088	39,998	41,774	30,178	0	0	0	0	8,221	0	0	2,272	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31
Cost Of Revenue	17,574	24,282	25,629	23,364	24,488	20,508	17,848	24,712	23,462	1,583	52,352	129	40,013	4,386	2,898	52,314	79,466	0	0	9,185
Depreciation And Amortization	3,010	1,516	1,478	2,864	1,505	1,527	1,750	10,933	12,972	2,254	1,495	1,495	1,495	1,831	1,425	531	572	575	424	377
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-13,952	6,329	42,165	27,239	22,810	21,738	-16,903	-18,571	-40,185	-135,170	-20,400	-28,225	-11,168	7,860	-35,948	-51,064	-80,110	-65,708	-24,287	-9,529
Ebitda	-13,952	7,845	43,643	30,103	24,315	23,265	-15,153	-7,638	-27,213	-132,916	-18,905	-26,730	-9,673	9,691	-34,523	-50,533	-79,538	-65,133	-23,863	-9,152
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	192,640	230,100	243,053	224,804	202,700	172,610	147,235	121,305	86,463	48,574	33,879	32,598	31,270	30,834	1,650	0	0	0	0	34
Income Before Tax	6,339	11,300	42,364	31,655	29,028	25,346	-15,431	-17,906	-39,865	20,186	-20,255	-27,664	-10,246	9,269	-35,859	-51,064	-74,060	-63,511	-23,877	-9,469
Income Tax Expense	3,830	5,025	9,212	8,318	-86,525	138	136	104	0	-77,616	0	0	-444	2,077	0	1,781	10	1	8	5
Interest Expense	0	4,971	199	4,416	6,218	0	0	0	0	0	0	0	0	0	0	0	0	4,833	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	2,509	6,275	33,152	23,337	115,553	25,208	-15,567	-18,010	-39,865	20,186	-20,255	-27,664	-9,802	7,192	-35,859	-51,064	-74,070	-63,511	-23,884	-9,474
Net Income Applicable To Common Shares	0	6,275	33,152	23,337	115,553	25,208	-15,567	-18,010	-39,865	20,186	-20,255	-27,664	-9,802	7,192	0	0	0	0	0	0
Net Income From Continuing Ops	11,770	6,275	33,152	23,337	115,553	25,246	-15,567	-18,010	-40,185	20,062	-20,255	-27,664	-9,802	0	0	0	0	0	0	0
Net Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	0	0	0	0	0	0	0	0	0	0	461	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	-77,616	0	0	0	0	0	0	0	0	0	0
Operating Income	-13,952	6,329	42,165	27,239	22,810	21,738	-16,903	-18,571	-40,185	20,062	-20,400	-28,225	-10,707	8,349	-35,948	-52,845	-80,038	-65,708	-24,287	-9,528
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	206,592	248,053	226,517	220,929	204,378	171,380	181,986	164,588	150,110	107,711	54,279	60,952	41,977	26,871	40,496	52,845	80,038	65,708	24,287	9,562
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	2,515	2,733	2,841	2,864	2,892	2,956	2,984	0	0	0	0	0	0	0	0	0	0	0	0	0
Research Development	76,823	85,770	75,363	55,577	48,649	43,594	38,547	29,156	29,145	19,230	28,190	45,446	28,996	12,338	13,874	23,936	47,235	52,071	16,891	7,443
Selling And Marketing Expenses	0	2,600	6,700	12,600	3,200	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	122,052	133,885	117,347	127,910	126,536	105,751	123,841	99,787	84,531	84,644	24,594	13,882	11,486	10,147	23,724	28,910	32,804	13,638	23,863	0
Tax Provision	5,843	5,025	9,212	8,318	-86,525	138	136	104	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	206,592	223,771	200,888	197,565	179,890	150,872	164,138	139,876	126,648	106,128	54,279	60,823	41,977	22,485	37,598	52,845	80,038	65,708	24,287	9,562
Total Other Income Expense Net	20,291	4,971	199	4,416	6,218	3,608	1,472	665	320	77,740	145	561	461	489	89	1,781	71	2,198	0	0
Total Revenue	192,640	254,382	268,682	248,168	227,188	193,118	165,083	146,017	109,925	50,157	33,879	32,727	31,270	35,220	4,548	0	0	0	0	34

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31
Cost Of Revenue	3,460	3,063	3,499	4,774	6,238	6,320	6,059	5,665	6,236	6,797	6,566	6,030	6,412	5,898	5,847	5,207	6,225	6,782	6,368	5,113	5,667	5,068	5,213	4,560	4,791	4,525	4,529	4,003	5,272	6,990	6,494	5,956	6,171	6,510	5,766	5,015	682	703	198	35,031	16,086	13,654	11,255	12,157	129	13,202	15,998	15,758	13,716	10,739	8,510	-1,118	-1,118	377	1,888	1,744	2,291	377	229	6,434	7,527	11,049	13,799	19,939	21,922	23,369	17,498	16,677	0	0	0	0	0	0	0	0	9,185
Depreciation And Amortization	1,158	380	378	670	379	379	690	702	369	708	369	370	713	369	369	370	370	726	719	380	380	748	398	701	432	774	735	704	2,105	3,162	2,942	2,943	2,943	2,943	2,942	4,284	536	668	617	690	377	377	477	369	377	377	465	700	562	377	433	446	455	456	457	463	472	484	346	123	128	143	137	123	125	153	145	149	160	151	144	120	107	106	97	113	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-7,094	-5,995	-2,867	2,004	6,629	3,908	3,461	-7,669	8,636	10,819	12,369	10,341	10,451	7,742	9,171	-125	4,243	10,759	9,895	-2,087	9,150	6,233	3,913	2,442	-2,150	-4,923	-1,924	-7,906	-654	-653	-4,789	-12,475	-14,893	-9,541	-5,458	-10,293	-85,539	-1,448	-21,606	-26,578	-7,667	-5,405	-3,109	-4,219	-6,428	-5,395	-8,085	-8,672	-5,908	-3,293	-1,513	7	791	288	1,071	6,147	-9,326	-8,219	-12,392	-6,504	-5,874	-11,193	-13,936	-20,062	-22,048	-23,593	-17,643	-16,826	-12,407	-12,807	-22,080	-18,414	-7,058	-5,757	-5,534	-5,938	0
Ebitda	-5,936	-5,615	-2,489	2,674	7,008	4,287	4,151	-6,967	9,005	11,527	12,738	10,711	11,164	8,111	9,540	245	4,613	11,485	10,614	-1,707	9,530	6,981	4,311	3,143	-1,718	-4,149	-1,189	-7,202	1,451	2,509	-1,847	-9,532	-11,950	-6,598	-2,516	-6,009	-85,003	-780	-20,989	-25,888	-7,290	-5,028	-2,632	-3,850	-6,051	-5,018	-7,620	-7,972	-5,346	-2,916	-1,080	453	1,246	744	1,528	6,610	-8,855	-7,735	-12,046	-6,381	-5,746	-11,049	-13,799	-19,939	-21,923	-23,440	-17,498	-16,677	-12,247	-12,656	-21,937	-18,293	-6,951	-5,651	-5,437	-5,825	0
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	41,811	35,752	42,557	57,724	58,244	58,998	58,331	54,527	61,783	63,298	61,333	56,639	61,241	54,410	56,360	52,793	54,705	52,703	52,692	42,600	47,374	44,067	42,137	39,032	39,485	36,811	37,527	33,412	32,972	31,492	29,535	27,306	25,678	21,834	21,816	17,135	14,688	14,079	10,664	9,143	8,783	8,709	8,319	8,068	7,791	8,288	8,378	8,141	8,370	7,969	7,430	7,501	8,870	6,870	6,402	10,677	2,256	-377	-229	0	0	0	0	3,465	0	0	0	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-1,661	-120	2,592	5,528	9,613	5,461	3,790	-7,564	8,610	10,722	12,604	10,428	10,924	8,401	11,089	1,241	5,810	12,276	11,544	-602	10,318	7,263	4,701	3,064	-1,751	-4,527	-1,527	-7,626	-500	-430	-4,618	-12,358	-14,798	-9,461	-5,386	-10,221	69,719	-1,426	-21,575	-26,533	-7,623	-5,380	-3,079	-4,173	-6,369	-5,326	-8,007	-7,962	-5,809	-3,187	-1,392	142	933	899	1,242	6,195	-9,237	-7,725	-12,392	-6,504	-7,504	-10,869	-13,495	-19,196	-20,749	-21,936	-15,983	-15,392	-11,891	-12,124	-21,373	-18,122	-6,836	-5,705	-5,468	-5,867	0
Income Tax Expense	739	-257	1,072	2,276	2,752	2,191	1,216	-1,134	1,532	2,951	2,951	1,778	2,734	2,454	2,375	755	1,594	-88,147	18	10	-42	92	90	-2	87	23	7	19	104	0	0	0	0	0	0	0	-77,616	0	0	0	0	0	0	0	0	0	0	-355	-286	-113	-51	6	-1,266	-2,285	-38	5,665	-84	-484	21	53	1,781	0	0	0	0	8	2	1	549	0	0	0	8	0	0	-70	5
Interest Expense	0	0	0	3,524	2,984	1,553	329	105	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,833	396	1,625	2,809	5	5	6	10	42
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-2,400	137	1,520	3,252	6,861	3,270	2,574	-6,430	7,078	7,771	9,653	8,650	8,190	5,947	8,714	486	4,216	100,423	11,526	-612	10,360	7,171	4,611	3,066	-1,838	-4,550	-1,534	-7,645	-604	-430	-4,618	-12,358	-14,798	-9,461	-5,386	-10,221	69,719	-1,426	-21,575	-26,533	-7,623	-5,380	-3,079	-4,173	-6,369	-5,326	-8,007	-7,962	-5,523	-3,074	-1,341	136	2,199	3,184	1,279	529	-9,237	-7,725	-12,392	-6,504	-7,504	-10,869	-13,495	-19,196	-20,748	-21,944	-15,985	-15,393	-11,891	-12,124	-21,373	-18,122	-6,844	-5,705	-5,468	-5,867	0
Net Income Applicable To Common Shares	0	0	1,520	3,252	6,861	3,270	2,574	-6,430	7,078	7,771	9,653	8,650	8,190	5,947	8,714	486	4,216	100,423	11,526	-612	10,360	7,171	4,611	3,066	-1,838	-4,550	-1,534	-7,645	-604	-430	-4,618	-12,358	-14,797	-9,461	-5,386	-10,221	69,720	-1,426	-21,575	-26,533	-7,623	-5,380	-3,079	-4,173	-6,369	-5,326	-8,007	-7,962	0	-3,074	-1,341	136	2,199	3,184	1,280	529	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-2,400	137	1,520	3,252	6,861	3,270	2,574	-6,430	7,078	7,771	9,653	8,650	8,190	5,947	8,714	486	4,216	100,423	11,526	-612	10,398	7,171	4,611	3,066	-1,838	-4,550	-1,534	-7,645	-93	-653	-4,789	-12,475	-14,893	-9,541	-5,458	-10,293	69,618	-1,448	-21,575	-26,533	-7,623	-5,380	-3,079	-4,173	-6,369	-5,326	-8,007	-7,962	0	-3,074	-1,341	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	106	121	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-77,616	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-7,094	-5,995	-2,867	2,004	6,629	3,908	3,461	-7,669	8,636	10,819	12,369	10,341	10,451	7,742	9,171	-125	4,243	10,759	9,895	-2,087	9,150	6,233	3,913	2,442	-2,150	-4,923	-1,924	-7,906	-654	-653	-4,789	-12,475	-14,893	-9,541	-5,458	-10,293	69,693	-1,448	-21,606	-26,578	-7,667	-5,405	-3,109	-4,219	-6,428	-5,395	-8,085	-8,317	-5,908	-3,293	-1,513	7	791	744	1,156	6,147	-9,242	-7,735	-12,413	-6,557	-7,655	-11,193	-13,936	-20,062	-22,048	-23,522	-17,643	-16,826	-12,407	-12,807	-22,080	-18,414	-7,058	-5,757	-5,534	-5,938	0
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	52,365	44,810	48,923	60,494	57,853	61,410	60,929	67,861	59,383	59,276	55,530	52,328	57,202	52,566	53,036	58,125	56,687	48,726	49,165	49,800	43,891	42,902	43,437	41,150	46,426	46,259	43,980	45,321	38,898	39,135	40,818	45,737	46,742	37,885	33,040	32,443	23,293	16,230	32,468	35,721	16,450	14,114	11,428	12,287	14,348	13,683	16,463	16,458	14,278	11,262	8,943	7,494	6,961	6,503	7,134	6,274	13,790	7,735	12,413	6,557	7,655	11,193	13,936	20,062	22,048	23,522	17,643	16,826	12,407	12,807	22,080	18,414	7,058	5,757	5,534	5,938	0
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	1,158	380	378	670	663	678	690	702	706	708	369	715	713	718	712	721	735	726	719	712	752	748	755	701	771	774	735	704	2,386	3,162	3,158	3,162	3,105	3,100	3,065	4,284	670	668	756	690	488	486	477	476	482	481	465	700	562	523	433	446	455	456	457	463	472	484	346	123	128	143	137	123	125	153	145	149	160	151	144	120	107	106	97	113	0
Research Development	24,339	16,600	16,647	19,237	18,454	24,857	21,490	20,969	19,331	19,653	20,248	16,131	14,849	12,298	12,903	15,527	13,074	11,347	10,950	13,278	12,922	11,390	9,866	9,416	10,154	10,178	7,648	10,567	7,614	7,294	6,700	7,548	8,747	9,974	5,946	4,478	4,752	3,701	3,514	7,263	6,222	8,026	5,982	7,960	10,617	10,159	12,490	12,180	10,556	8,174	5,999	4,267	3,822	4,072	2,404	2,041	2,253	2,092	7,196	2,333	3,560	3,792	5,481	11,103	12,575	13,874	10,194	10,592	7,940	9,542	19,100	15,489	5,249	4,092	3,672	3,878	7,443
Selling And Marketing Expenses	0	0	0	0	2,600	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,922,023	0	0	0	0	0
Selling General Administrative	23,613	24,767	28,399	36,104	30,182	29,854	33,001	40,848	33,447	32,456	28,347	29,797	35,571	34,001	33,917	37,021	37,018	30,221	31,468	31,029	24,922	26,047	27,960	26,822	31,049	31,124	31,371	30,297	23,907	21,908	24,682	29,290	28,881	18,458	18,386	18,806	17,323	11,290	28,139	27,893	9,851	5,711	5,074	3,958	3,225	3,147	3,601	3,909	3,345	2,711	2,572	2,858	2,762	2,054	2,842	2,489	9,245	5,266	4,988	4,224	4,095	7,400	8,455	8,959	9,473	9,648	7,449	6,234	4,467	3,265	2,981	2,924,948	6,951	5,650	5,438	5,824	0
Tax Provision	739	-257	1,072	2,276	2,752	2,191	1,216	-1,134	1,532	2,951	2,951	1,778	2,734	2,454	2,375	755	1,594	-88,147	18	10	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	48,905	41,747	45,424	55,720	51,615	55,090	54,870	62,196	53,147	52,479	48,964	46,298	50,790	46,668	47,189	52,918	50,462	41,944	42,797	44,687	38,224	37,834	38,224	36,590	41,635	41,734	39,451	41,318	33,626	32,145	34,324	39,781	40,571	31,375	27,274	27,428	22,611	15,527	32,270	35,721	16,450	14,114	11,428	12,287	14,219	13,683	16,463	16,458	14,278	11,262	8,943	7,494	8,079	6,126	5,245	4,530	11,498	7,358	12,184	6,557	7,655	11,193	13,936	20,062	22,048	23,522	17,643	16,826	12,407	12,807	22,080	18,414	7,058	5,757	5,534	5,938	0
Total Other Income Expense Net	5,433	5,875	5,459	3,524	2,984	1,553	329	105	-26	-97	235	87	473	659	1,918	1,366	1,567	1,517	1,649	1,485	1,168	1,030	788	622	399	396	397	280	154	223	171	117	95	80	72	72	77,642	22	31	45	44	25	30	46	59	69	78	355	99	106	121	135	142	156	85	47	5	10	21	53	151	323	441	866	1,299	71	1,660	1,434	516	683	707	291	222	52	66	0	0
Total Revenue	45,271	38,815	46,056	62,498	64,482	65,318	64,390	60,192	68,019	70,095	67,899	62,669	67,653	60,308	62,207	58,000	60,930	59,485	59,060	47,713	53,041	49,135	47,350	43,592	44,276	41,336	42,056	37,415	38,244	38,482	36,029	33,262	31,849	28,344	27,582	22,150	15,370	14,782	10,862	9,143	8,783	8,709	8,319	8,068	7,920	8,288	8,378	8,141	8,370	7,969	7,430	7,501	7,752	7,246	8,290	12,421	4,548	0	0	0	0	0	0	3,465	0	0	0	0	0	0	0	0	0	0	0	0	34

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	192,640
Cost of Revenue	-17,574
Gross Profit	192,640	175,066

Operating Income (+$)
Gross Profit	192,640
Operating Expense	-206,592
Operating Income	-13,952	-13,952

Operating Expense (+$)
Research Development	76,823
Selling General Administrative	122,052
Selling And Marketing Expenses	0
Operating Expense	206,592	198,875

Net Interest Income (+$)
Interest Income	0
Interest Expense	-0
Other Finance Cost	-0
Net Interest Income	0

Pretax Income (+$)
Operating Income	-13,952
Net Interest Income	0
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	6,339	-34,243 EBIT - interestExpense = -13,952 6,339 2,509
Interest Expense	0
Earnings Before Interest and Taxes (EBIT)	-13,952	6,339
Earnings Before Interest and Taxes (EBITDA)	-13,952

After tax Income (+$)
Income Before Tax	6,339
Tax Provision	-5,843
Net Income From Continuing Ops	11,770	496
Net Income	2,509
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	206,592
Total Other Income/Expenses Net	20,291	0

Technical Analysis of Vanda Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Vanda Pharmaceuticals Inc. The general trend of Vanda Pharmaceuticals Inc is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Vanda Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (42.9%)		Bearish trend (-42.9%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Vanda Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.45 < 6.03 < 6.04.

The bearish price targets are: 3.71 > 3.46 > 3.46.

Tweet this

Vanda Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Vanda Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

MA 20 trending up: The MA 20 is trending up. +1
Close > MA 20: The price is above the MA 20. +1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
MA 50 trending up: The MA 50 is trending up. +1
Close > MA 50: The price is above the MA 50. +1
MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
MA 100 trending up: The MA 100 is trending up. +1
Close > MA 100: The price is above the MA 100. +1
MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
MA 200 trending down: The MA 200 is trending down. -1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Vanda Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Vanda Pharmaceuticals Inc. The current macd is 0.195967.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vanda Pharmaceuticals Inc price going up in the near term. +2
MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Vanda Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Vanda Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Vanda Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Vanda Pharmaceuticals Inc. The current adx is 31.63.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Vanda Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.

Vanda Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Vanda Pharmaceuticals Inc. The current sar is 4.0187.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

Vanda Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Vanda Pharmaceuticals Inc. The current rsi is 63.70. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Vanda Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Vanda Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Vanda Pharmaceuticals Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Vanda Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Vanda Pharmaceuticals Inc. The current cci is 108.36.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1

Vanda Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Vanda Pharmaceuticals Inc. The current cmo is 32.62.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1

Vanda Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Vanda Pharmaceuticals Inc. The current willr is -42.59259259.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Vanda Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Vanda Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Vanda Pharmaceuticals Inc. The current atr is 0.37052695.

Vanda Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Vanda Pharmaceuticals Inc. The current obv is 41,664,183.

Vanda Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Vanda Pharmaceuticals Inc. The current mfi is 79.94.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

Vanda Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Vanda Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-28	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2023-11-30	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-01	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-05	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-06	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-08	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-15	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-18	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2023-12-21	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-26	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-27	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-29	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-03	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-05	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-01-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-10	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-11	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-16	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-01-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-19	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-01-22	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-01-23	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-01-24	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-01-25	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-30	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-05	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-06	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-08	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-12	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-15	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-23	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-26	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-02-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-04	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-03-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-06	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-07	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-11	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-12	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-13	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-15	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-21	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-25	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-03-28	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-01	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-03	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-04-04	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-04-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-09	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2024-04-10	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-11	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-12	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-04-17	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-04-18	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside

6.3. Candlestick Patterns

Vanda Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Vanda Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	63.699
Ma 20	Greater than	Ma 50	4.371
Ma 50	Greater than	Ma 100	4.236
Ma 100	Greater than	Ma 200	4.054
Open	Greater than	Close	4.940
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about Vanda Pharmaceuticals Inc

I send you an email if I find something interesting about Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Vanda Pharmaceuticals Inc together

Get notifications about Vanda Pharmaceuticals Inc

Quick analysis of Vanda Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Vanda Pharmaceuticals Inc (5 min.)

$5.11

$9.47

$-16.58 - $7.78

$-7.11 - $17.25

2. Growth of Vanda Pharmaceuticals Inc (5 min.)

Is Vanda Pharmaceuticals Inc growing?

How much money is Vanda Pharmaceuticals Inc making?

How much money comes from the company's main activities?

3. Financial Health of Vanda Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc? (5 min.)

What can you expect buying and holding a share of Vanda Pharmaceuticals Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Vanda Pharmaceuticals Inc

About Vanda Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Vanda Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Vanda Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Vanda Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Vanda Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Vanda Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Vanda Pharmaceuticals Inc
Buy, Hold or Sell?